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The New Role of Proprotein Convertase Subtilisin/Kexin Type 9: 
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Apolipprotein B, and Autophagy  
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Hua Sun 
Supervisory Professor: Ba-Bie Teng, Ph.D. 
Plasma low-density lipoprotein (LDL) levels are positively correlated with the incidence of 
coronary artery disease. In the circulation, the plasma LDL clearance is mainly achieved by the 
uptake via LDL receptor (LDLR). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a newly 
discovered gene, playing an important role in LDL metabolism. Gain-of-function mutations of 
PCSK9 lead to hypercholesterolemia and loss-of-function mutations of PCSK9 are associated with 
decrease of LDL cholesterol. The effects of PCSK9 on cholesterol levels are the consequence of a 
strong interaction between the catalytic domain of PCSK9 and epidermal growth factor-like repeat A 
(EGF-A) domain of LDLR on the cell surface of hepatocytes. This PCSK9/LDLR complex enters 
the cell via endocytosis, where both PCSK9 and LDLR are removed via the lysosome pathway, 
resulting in decreased levels of LDLR and accumulation of LDL in the plasma. However, whether 
this is the exclusive function of PCSK9 on LDL metabolism was challenged by us; we observed 
PCSK9 interacted with apolipoprotein B (apoB) and increased apoB production, irrespective of the 
LDLR. 
ApoB is the primary structure protein of LDL particle and it also serves as the ligand for the 
LDL receptor. There is ample evidence showing that the levels of apoB are a better indicator for 
heart disease than either total cholesterol or LDL cholesterol levels. We used a second-generation 
adenoviral vector to overexpress PCSK9 (Ad-PCSK9) in wild-type C57BL/6 and LDLR deficient 
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mice (Ldlr-/- and Ldlr-/-Apobec1-/-). Our study revealed that overexpression of PCSK9 promoted 
the production and secretion of apoB in the form of very-low density lipoprotein (VLDL), which is 
the precursor of LDL, in the 3 mouse models studied (C57BL/6J, Ldlr-/-, and Ldlr-/-Apobec1-/-). 
The increased apoB production in mice was regulated at post-transcriptional levels, since there was 
no difference in apoB mRNA levels between mice treated with Ad-PCSK9 and control vector Ad-
Null. By using pulse-chase experiment on primary hepatocytes, we showed that overexpression of 
PCSK9 increased the secretion of apoB, independent of LDLR.  
In the circulation, we showed that PCSK9 was associated with LDL particles. By using 3 
different protein–protein interaction assays of co-immunoprecipitation, mammalian two-hybrid 
system, and in situ proximity ligation assay, we demonstrated a direct protein–protein interaction 
between PCSK9 and apoB.  The impact of this interaction inhibited the physiological removal 
process of apoB via autophagosome/lysosome pathway in an LDLR-independent fashion, resulting 
in increased production and secretion of apoB-containing lipoproteins. The significance of this 
process was shown in the Pcsk9 knockout mice in the background of Ldlr-/-Apobec1-/- mice (triple 
knockout mice); in the absence of Pcsk9 (triple knockout mice) the levels of cholesterol, 
triacylglycerol, and apoB decreased significantly in comparison to that of Ldlr-/-Apobec1-/- mice.  
Taken together, our study demonstrated a direct intracellular interaction of PCSK9 with apoB, 
resulting in the inhibition of apoB degradation via the autophagosome/lysosome pathway 
independent of LDLR.  This discovery provides a new concept of the importance of PCSK9 and 
suggests new approaches for the therapeutic intervention of hyperlipidemia.  
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INTRODUCTION 
1. PCSK9, a new target for cholesterol lowering drug 
1.1  PCSK9 and its genetic variants  
Proprotein convertase subtilisin/kexin type 9 (PCSK9) was initially discovered as a gene 
whose expression was up-regulated in the neural tissues. It belongs to the proteinase K subfamily of 
the subtilisin family (2). PCSK9 gene is located on human chromosome 1p34.1−p32, and is 
recognized as the third major locus for autosomal dominant hypercholesterolemia (ADH) (3). The 
LDL receptor (LDLR) and apolipoprotein B (apoB) genes are the other 2 loci for ADH.  
In 2003, Abifadel et al. studied 2 French families with the characteristics of ADH, who have 
no detectable mutations in LDLR or apoB genes. They were identified to carry the dominant point 
mutations (S127R and F216L) in PCSK9 (4, 5). Later on, many other mutations on PCSK9 were 
discovered. Most of these mutations are classified into 2 major functional categories: “gain-of-
function mutations,” which are associated with elevated level of LDL cholesterol and “loss-of-
function mutations,” which lead to lower level of LDL cholesterol (6) (Figure I-1).  Some of these 
mutations have been intensively investigated. For example, a gain-of-function D374Y variant, which 
was found in Utah, Norway, and England cohorts, shows an increased affinity to LDLR (5, 7-9). On 
the other hand, loss-of-function variants of Y142L and C679X, which have high frequencies in 
African Americans, lead to very low cholesterol levels (10-13). So far more than 40 PCSK9 gene 
mutations have been reported to be associated with either a gain or loss of function on PCSK9 
activity (increase or decrease cholesterol levels) (14). These mutations are located through the 5′ 
UTR region to the C-terminal domain of the gene. It would be a challenge to characterize the 
structure/function of each variant on LDL cholesterol levels. 
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Gain of Function High LDL cholesterol 
Loss of Function Low LDL cholesterol 
S127R  
F216L 
D374Y 
E670G 
R46L 
Y142L 
C679X 
Figure I-1.      Gain- and loss-of-function mutations of PCSK9.  
Since 2003, more than 100 mutations of PCSK9 have been reported. Gain-of-function mutations 
lead to high LDL cholesterol levels in plasma, which increases the risk of developing coronary 
heart diseases. On the other hand, loss-of-function mutations of PCSK9 decrease plasma LDL 
cholesterol levels and prevent coronary heart disease. The graph is adapted from Seidah  (1) with 
permission. 
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1.2. The action of PCSK9 on lipid metabolism 
Over-expression of PCSK9 in mice either by adenoviral vector (15) or using transgenic 
method (16) resulted in significant reduction of hepatic LDLR protein and, in turn, increase of 
plasma LDL cholesterol levels. Similar effects were observed when mice were infused with purified 
PCSK9 protein (17, 18). By contrast, Pcsk9-/- mice have approximately 3-fold more hepatic LDLR 
levels than that of wild-type C57BL/6 mice and a 5-fold increase in LDL clearance (19). These 
findings have led to intense investigations of PCSK9 in the regulation of LDL cholesterol levels, and 
PCSK9 has emerged as promising therapeutic target for the treatment of hypercholesterolemia.  
PCSK9, a 692-amino acid glycoprotein, is synthesized in the liver as a ~74 kDa enzyme 
precursor (zymogen) that undergoes autocatalytic processing, and thereby a pro-domain (14 kDa) is 
cleaved at the N-terminus at residue 152 (20). The pro-domain attaches noncovalently to the mature 
peptide that is secreted and then enters the circulation. The formation of this complex abrogates the 
catalytic activity of PCSK9, and so far no other substrates have been found except PCSK9 itself (21). 
Once in the circulation, this PCSK9 complex binds to the LDLR extracellular epidermal growth 
factor homology domain (EGF-A) on the hepatocyte surface (22, 23). The LDLR/PCSK9 complex is 
internalized via clathrin-coated pits and goes through endosome to lysosome for degradation. The 
binding affinity of PCSK9/LDLR in the endosome is very high, which prevents the dissociation of 
the complex and promotes the degradation of LDLR via lysosome (24), resulting in reduced numbers 
of the LDLR and hence, increased the plasma LDL-cholesterol levels (22, 25, 26) (Figure I-2). 
Studies demonstrated that gain-of-function mutation of PCSK9-D374Y, in which PCSK9 attains 50-
fold higher affinity to LDLR and thus promotes LDLR degradation than that of the wild-type PCSK9 
(5, 27). The pro-domain gain-of-function mutation of PCSK9-S127R interacts with the β-propeller of 
LDLR via van der Waals force, which also demonstrates a high affinity binding of PCSK9-S127R to 
LDLR (6). Moreover, the interaction of PCSK9 with LDLR in the endoplasmic reticulum 
compartment has also been reported (28). 
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The crystal structure of the interaction of PCSK9 catalytic domain and the EGF-A domain of 
LDLR has been reported (9, 29, 30). PCSK9 binds in a calcium-dependent manner to the first EGF-
A of the EGF-A domain of the LDLR (23). The catalytic domain is the only part of PCSK9 molecule 
contacts with EGF-A of LDLR; the key residues of PCSK9 that interact with the EGF-A domain are 
Arg-194 and Asp-238.  The residues of 367–381 form the surface for interaction. This region 
contains the Asp-374, which the gain-of-function mutation (D374Y) was reported in patients.  The 
interface between PCSK9 and LDLR forms a hydrophobic surface and Phe-379 of PCSK9 is the 
center of it. Residues 153–155 on the N-terminus of the catalytic domain of PCSK9 also contribute 
to the interaction (29). 
The integrity of LDLR EGF-A domain is very important for the maintenance of the receptor 
function. Several natural mutations in the EGF-precursor homology domain of LDLR that hinder 
receptor recycling are present in patients with FH (23, 24). The EGF-A and EGF-B tandem pair form 
an extended rod-like conformation stabilized by calcium binding and inter-domain hydrophobic 
packing interactions (25, 26). The interaction of EGF-A with the ligand-binding module R7 in LDLR 
confers a rigid conformation on this region of the LDLR across a wide pH range (27). This rigidity 
has been proposed to facilitate the acid-dependent closed conformation of the LDLR (28). The 
binding of PCSK9 towards EGF-A domain may disrupt the interaction between R7 and EGF-A 
domain, and leads to a reduced acid-dependent ligand release. It may finally promote the delivery of 
LDLR to the lysosome or prevent LDLR interaction with other proteins, which is required for LDLR 
recycling to the cell surface (23). 
The structure of PCSK9 in complex with the LDLR EGF-A domain defines the potential 
therapeutic target sites for blocking agents that could interfere with this interaction in vivo, thereby 
increasing LDLR function and reducing plasma LDL-C levels. 
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1.3 The regulation and pharmacological modulation of PCSK9  
PCSK9 is mainly synthesized in the liver, small intestine, and kidney (2, 15, 20). Like the 
LDLR, the levels of intracellular sterols regulate hepatic PCSK9 production; when the levels of 
cholesterol increase, the PCSK9 production decreases (31).  
Both PCSK9 gene expression and the PCSK9 levels in the circulation are affected by LDLR 
and enzymes in cholesterol biosynthesis such as HMG CoA synthase, HMG CoA reductase, or other 
factors that play roles in intracellular cholesterol homeostasis (32, 33). The regulation of PCSK9 by 
sterols is achieved by the increased binding of the sterol responsive element binding protein 2 
(SREBP-2), a key transcriptional factor, to the sterol responsive element (SRE) in the promoter 
region of PCSK9 gene. This regulation is demonstrated when depleting the intracellular cholesterol 
pool, resulting in promoting the translocation of SREBP-2 from ER to nuclei to activate PCSK9 
transcription (34, 35).  PCSK9 gene expression is also suppressed by glucagon, berberine, bile acids, 
or fasting (36, 37). All these regulations indicate the clinical significance of PCSK9, as it is 
recognized as an important cholesterol regulator. 
SREBP regulates the transcription of PCSK9, LDLR, and enzymes involved in cholesterol and fatty 
acid biosynthesis pathways.  SREBP belongs to the basic helix-loop-helix leucine zipper class of 
transcription factors. When cells have low levels of sterols, SREBP is cleaved and releases a water-
soluble N-terminal domain, which translocates to the nucleus. This cleaved SREBP N-terminal 
domain then binds to the specific SRE sequences and up-regulates the enzymes involved in sterol 
biosynthesis. Increased sterol levels, in turn, inhibit the cleavage of SREBP, and therefore decrease 
the synthesis of sterol through this negative feedback loop. 
Mammalian genomes have 2 separate SREBP genes (SREBP1 and SREBP2). SREBP-1 
produces 2 different isoforms, SREBP-1a and -1c. SREBP-1c is responsible for regulating genes for 
de novo lipogenesis. SREBP-2 regulates the genes of cholesterol biosynthesis. Thus, SREBPs are the 
main regulators for lipid metabolism. 
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Statin binds to HMG-CoA reductase, to inhibit the cholesterol biosynthesis. This inhibition 
decreases the levels of cholesterol, which activates the release of cleaved active form of SREBP-2. 
SREBP-2 activates the gene expressions of both LDLR and PCSK9. It is possible a balance between 
LDLR and PCSK9 governs whether statin is function beneficial for decreasing cholesterol levels. It 
has been shown that statin has no effect on patients with PCSK9-D374Y mutation (38). Patients with 
loss-of-function PCSK9 mutation of R46L, G106R, or R237W had increased LDLR and responded 
well to statin therapy (39). Thus a combination of statin with PCSK9 inhibitor therapy may be 
beneficial for a defined group of patients. The relationships of other cholesterol lowering drugs such 
as fenofibrates, bile acid binding resins, or ezetimibe with PCSK9 are not clear.  With more clinical 
data become available on the PCSK9 levels in the patients treated with various cholesterol lowering 
drugs, the potential role of PCSK9 inhibitor acts as a synergistic medication would become very 
promising.  
 
8 
 
1.4  The therapeutic strategies to knockdown PCSK9 levels 
Evidence demonstrates that Pcsk9 knockout mice are viable with very low cholesterol levels 
(16, 19). Individuals carrying loss-of-function mutations of PCSK9 have low LDL-cholesterol and 
live a normal life (12, 19, 39, 40). Moreover, an epidemiological study of Atherosclerosis Risk in 
Communities (ARIC) shows many loss-of-function mutations in PCSK9 are associated with low 
coronary artery disease (decreased 88%) (10). Thus, therapeutics aiming to decrease PCSK9 levels is 
warranted. 
There are several strategies that have been developed to regulate PCSK9 function. The most 
straightforward one is by using monoclonal antibodies to block the interaction between PCSK9 and 
LDLR in the circulation. Currently monoclonal antibodies produced from both Amgen and 
Regeneron are in Phase I clinical trials (41). These antibodies blocked the interaction of PCSK9 with 
LDLR, resulting to a significant reduction in LDL cholesterol levels for 3 days after antibody 
administration and the effect lasted for 7–10 days (42).  
Mice treated with antisense oligonucleotides targeted at PCSK9 decreased triglyceride and 
cholesterol levels significantly (reduction of 65% and 53%, respectively) (43).  Recently, a PCSK9 
lipidoid nanoparticle (LNA) antisense oligonucleotide was shown to reduce the PCSK9 mRNA and 
serum PCSK9 protein by 85% and 55%, respectively, which resulted in a 50% reduction of 
circulating LDL cholesterol in nonhuman primates (44). PCSK9-specific siRNA almost completely 
eliminated the production of hepatic and plasma PCSK9 at day 3 after one treatment in nonhuman 
primates (45). Taken together, all these strategies shed some light on potential therapeutic 
application of PCSK9 in the treatment of hyperlipidemia. 
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2.  Apolipoprotein B and Lipoproteins metabolism 
2.1  VLDL, LDL, and HDL, their roles in atherosclerosis development 
Lipoprotein particles are a group of protein and lipid assembled together serving as 
hydrophobic lipids transporter. According to their density and size, lipoprotein particles are generally 
classified as chylomicron, very low-density lipoprotein (VLDL), intermediate density- lipoprotein 
(IDL), low density-lipoprotein (LDL), and high density-lipoprotein (HDL). Triglyceride and 
cholesteryl ester are in the center core of lipoprotein particles, which are surrounded by a monolayer 
of phospholipids, unesterified cholesterol, and apolipoproteins. Each class of lipoprotein contains a 
different kind of apolipoproteins including apolipoprotein B (apoB), apoE, apoAI, apoAII, apoCI, 
apoCII, apoCIII, and apoD.  VLDL, LDL, and HDL have been shown as important cardiovascular 
diseases (CVD) risk factors and many interventions have been developed to alter the levels of 
lipoprotein for the prevention and treatment of CVD (Figure I-3). 
The metabolism of lipoprotein is very complicated. It begins from the absorption of fats in 
the small intestine. Enterocytes package the fats with apoB as chylomicron, and secrete to the 
circulation. Chylomicrons undergo lipolysis to become chylomicron remnants, which are taken up by 
the liver via chylomicron receptor.  In the liver, VLDL is assembled and secreted to the circulation as 
apoB-containing triglyceride-rich lipoprotein particles. VLDL undergoes lipolysis to become IDL 
and LDL; there is a precursor-product relationship. The process of VLDL to LDL, which takes 2 to 
10 h, is fast.  LDL is cholesterol ester enrich lipoprotein particles.  It has a normal half-life of 3 days 
before they are removed from plasma via LDLRs on the surface of hepatocytes.  The internalized 
LDLs are degraded in the lysosomes, and the liberated cholesterol enters the cellular cholesterol 
pool. The LDL receptor recycles back to the cell membrane, and the number of LDLRs on the 
hepatocytes’ surface determine the removing rate of plasma LDL (46).  
HDL is the smallest and densest lipoprotein particles in the circulation. It is secreted from 
the liver as a nascent HDL disc containing apoAI and apoAII and phospholipids. HDLs are 
protective lipoprotein particles of cardiovascular diseases (although their protective role is 
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questioned recently). The major biological function of HDL is reverse cholesterol transport, a very 
important biological process in mammalians to remove excess cholesterol from periphery tissues, 
including the artery wall, back to the liver. Many enzymes and molecules participate in this process. 
ATP-binding cassette transporter A1 (ABCA1) initiates the process by mediating the efflux of 
cholesterol and phospholipids across extra- and intracellular membranes (47). Some other 
transporters, such as ATP-binding cassette sub-family G member 1 (ABCG1) and phospholipids 
transport protein (PLTP) are also involved in this lipid loading process (48, 49). In this process, the 
protein dominant nascent HDL particles gradually transform into larger, spherical HDL by being 
loaded with cholesterol and phospholipids. The free cholesterol is then converted by lecithin-
cholesterol acyltransferase (LCAT) to cholesteryl ester, which is sequestered into the core of 
lipoprotein (50).  
In the circulation, VLDL and LDL transfer triglyceride to HDL, in exchange for the CE via a 
transfer protein named cholesteryl ester transfer protein (CETP), also called plasma lipid transfer 
protein (51). CETP is positively associated with atherosclerosis. Recently, a small molecular agent 
named Torcetrapib has been designed to inhibit the activity of CETP; however, even though 
Torcetrapib treatment increases HDL levels by 60%, the cardiovascular endpoints were not achieved 
but had early death in patients (52). This study was terminated prematurely. New CETP inhibitors 
such as Dalceltrapid and Anacetrapid are continuously being investigated for long-term effects on 
coronary artery diseases development (53). 
Atherosclerosis is a chronic inflammatory response to the accumulated lipids such as LDL in 
the artery wall. Although the main cause of atherosclerosis still remains unknown, high levels of 
LDL particles in the circulation is the most important and necessary initial event of atherosclerosis. 
In the intima of the artery wall, the LDLs are oxidized to ox-LDLs, which recruits macrophages and 
T lymphocytes to initiate immune responses. Macrophages uptake the ox-LDLs and convert into 
foam cells and eventually the atherosclerotic plagues.  
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Generally, in atherogenesis, VLDL and LDL are considered as the culprits of the disease 
while the HDL is considered as the protective factor. Most of the interventions are focused on 
achieving a low LDL cholesterol level, and a higher HDL level.  Statins are the most successful class 
of drugs to lower LDL cholesterol. The main mechanism of action of statin is blocking cholesterol 
synthesis by competitively inhibiting HMG-CoA reductase. By doing so, lowered liver-cell 
cholesterol levels stimulate SREBP-2 transcriptional factor to translocate into nuclei and activate the 
transcription of LDLR, which uptake LDL from circulation (54, 55). Although statins have side 
effects such as rhabdomyolysis, their effects on lowering LDL-cholesterol are far better than other 
classes of lipid lowering drugs such as fibrates, or niacin, or bile acid sequestrants, or ezetimibe (56). 
Other drugs such as niacin and fibrates can increase HDL cholesterol levels. However, statins have 
little effect on HDL cholesterol levels. 
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Figure I-3. The biosynthesis of LDL and its effects on atherosclerosis.  
Liver produces VLDLs to deliver lipids for peripheral utilization. VLDLs gradually lose 
triglycerides in the peripheral tissues such as adipose and muscle, exchange their protein and 
lipid contents with other lipoproteins, and finally become cholesterol ester enriched particles; 
LDLs. The physiological function of LDL is to transport cholesterol to peripheral tissues, 
however, modified LDLs such as oxidized LDLs deposit in the arterial wall and initiate 
atherosclerosis. LDLs in the blood can also be removed via the LDLR on the surface of 
hepatocytes. The expression of the LDLR on the hepatocytes is critical for the regulation of 
LDL cholesterol levels in the circulation. 
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2.2.  Apolipoprotein B, the structure protein of chylomicron, VLDL, and LDL  
Apolipoprotein B (ApoB) is the major structural protein of chylomicron, VLDL, and LDL 
particles in vertebrates. In plasma, the clearance of LDL depends on the interaction of apoB with the 
LDLR in a ligand and receptor binding fashion (57) (Figure I-4A). Thus, apoB plays an essential role 
in apoB-containing lipoprotein homeostasis.  
The human APOB gene (43 kb) resides on chromosome 2p and is expressed mainly in the 
hepatocytes and enterocytes (58). The apoB mRNA is translated into a full-length apoB-100 
consisting of 4,536 amino acids in the liver. A truncated form of apoB, known as apoB-48, 
represents the N-terminal 48% of apoB-100 and is produced in the intestine by an RNA editing 
mechanism (59). The editing enzyme is known as the apoB mRNA-editing enzyme catalytic 
polypeptide 1 (Apobec1), which converts a C to a U to generate an in-frame stop codon (60) (Figure 
I-4B). In humans, apoB-100 is the obligatory structural protein for the assembly and secretion of 
hepatic VLDL. In rodents, the liver synthesizes and secretes both apoB-100 and apoB-48 containing 
VLDL, whereas mice that lack Apobec1 gene (Apobec1-/-), secrete only apoB-100 containing 
lipoproteins (61-63).  
The plasma LDL cholesterol (LDL-C) level has been used as the primary risk factor of 
coronary heart diseases (CHD) for a long time. However, emerging findings suggest that other 
indicators such as non-HDL-C or apoB are much more accurate markers than LDL cholesterol 
levels, especially for patients with elevated triglycerides or with an LDL-C <100 mg/dL (64-66). 
ApoB has been reported by many studies to be strongly associated with CHD risk compared with 
other conventional measures (67-70). Furthermore, the ratio of apoB to apoAI is suggested to be a 
better predictor for disease risk than LDL cholesterol alone (71). Thus, apoB is a potential 
therapeutic target for the treatment of CHD. 
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(A) 
(B) 
Figure I-4. ApoB structure and its mRNA editing. 
 (A) The organization of apoB100 on the low-density lipoprotein particle. ApoB100 (yellow 
band) spans the entire circumference of the LDL particle, which has phospholipid surface and 
cholesterol ester core. Sites A and B are the binding sites for its receptor: LDL receptor. (B) 
The mRNA editing of apoB. In the small intestine of all mammals, apobec-1 converts apoB 
mRNA cytidine-6666 to uridine, and forms a UAA stop codon. As a result, a truncated 
protein consisting of the N-terminal 48% of apoB is produced, namely apoB48. In rodents 
apobec1 is also expressed in liver, resulting in significant hepatic production of apoB48-
containing lipoproteins. 
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2.3 The regulation of apoB and its degradation process 
The apoB mRNA contains 28 exons and 29 introns. ApoB mRNA is constitutively 
expressed, and it is regulated at post-transcriptional level. The regulation of apoB translation is 
mainly through the mRNA sequence in the 5′UTR and the 3′UTR. The GC rich region in 5’UTR and 
AU rich region in 3′UTR change the stability of apoB mRNA and therefore affect apoB translation. 
Generally, the 5′UTR increases the translation of apoB while 3’UTR decreases the translation of 
apoB (72, 73).  Insulin has been reported as a negative regulatory factor for apoB production. It may 
interact with a 64nt region of 5′UTR and attenuate apoB translation. A 110- kDa insulin sensitive 
factor binds to 5’UTR of apoB mRNA mediates apoB translation (74).  
Microsomal triglyceride transfer protein (MTP) also plays a very important role in the 
regulation of apoB production. Individuals with a mutation of Mtp gene, which leads to dysfunction 
of MTP, have no apoB in the plasma (75). MTP is associated with N-terminal β-barrel and α-helix 
regions of apoB (76, 77). The role of MTP in VLDL production is unclear; MTP assists lipids and 
lipidated apoB in crossing the ER membrane and promote VLDL production and secretion (78). In 
the abscence of MTP, nascent apoB will be degraded.  
The secretion of ApoB as VLDL is mainly regulated at post-transcriptional levels (79, 80).  
ApoB mRNAs are constitutively translated to apoB protein; however, most of the apoB are destined 
to degradation. There are 3 major ways for apoB degradation. The first one is that newly synthesized 
apoB can be internalized by LDLR or heparin sulfate proteoglycans when it arrives at cell surface. 
The second way is an ubiquitin-proteasome system that recycles all the apoB that failed to be 
lipidated as described above. Several protein chaperons, such as heat shock protein (HSP) 70, HSP 
90, Hsp110, p97, and BiP participated in this process (81-88). The third one is called post-ER, pre-
secretory proteolytic process (PERPP). This process has been suggested as an autophagic process 
(89). 
In eukaryotes, autophagy is an evolutionarily conserved process to get rid of misfolded or 
long half-life proteins, or damaged organelles, or intracellular microorganism. Autophagy can 
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provide nutrients and energy by recycling extracellular materials when cells are exposed to various 
stresses. The autophagy process can be described as cytoplasmic cargo sequestered inside double-
membrane vesicles to deliver materials to the lysosome for degradation.  
In human Huh7 cell, lipid droplets associated with apoB100 molecules are detected in 
autophagosomes (90, 91). In McArdle RH-7777 (McA-RH7777) cell line, the apoB100 was also 
detected in autophagosomes, and increased apoB degradation was observed when the cells were 
treated with glucosamine to induce ER-stress. This degradation could be blocked by an inhibitor of 
autophagy: 3-methyl adenine (3-MA) (92). Thus, the autophagy process may represent an important 
regulatory pathway for apoB. We predicted that the reduction of autophagy degradation of apoB 
would accompany increased VLDL production. Further understating of the apoB degradation 
pathways may lead to the novel therapeutic strategies to lower VLDL production and reduce the risk 
of atherosclerosis.  
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3.  The effect of PCSK9 on apoB production  
Although it is well established that PCSK9 negatively regulates LDLR expression, whether 
or not PCSK9 has an impact on apoB production remains controversial and poorly understood. McA-
RH7777 cells expressing the D374Y mutant of PCSK9 secrete an increased amount of apoB than 
that expressing either the wild-type PCSK9 or a non-functional mutant, S386A (5). An increased rate 
of apoB production was also observed in patients with the S127R mutation in PCSK9 (10). 
Overexpression of the wild-type PCSK9 or the S127R mutant in C57BL/6 and Ldlr-/- mice for 3 
days, however, did not result in significant increase in apoB synthesis or production (11). Similar 
insignificant changes of plasma apoB levels were also observed in C57BL/6 and Ldlr-/- mice over-
expressing PCSK9 for 5 days (12). However, when the study was extended to 6 days after 
adenovirus injection, significant increased plasma cholesterol, triacylglycerol (TAG), and apoB were 
observed in C57BL/6 mice, while overexpression of PCSK9 still had no effect on the Ldlr-/- mice 
(13). On the other hand, another group reported that overexpression of PCSK9 in Ldlr-/- mice for 7 
days resulted in an approximately 2-fold increase in LDL-cholesterol and apoB (14). The apparent 
discrepancies among these experiments did not provide conclusive evidence for a causative effect of 
PCSK9 expression on apoB and apoB-containing lipoproteins. However, the increased apoB 
production in Ldlr-/- mice overexpressing PCSK9 (14) does suggest an LDLR-independent 
mechanism by which PCSK9 expression exerts an impact on apoB production. Thus, it is important 
to investigate whether PCSK9 plays a role in apoB production in a LDLR independent fashion. This 
was the central theme of this thesis. 
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STATEMENT OF OBJECTIVES 
PCSK9 is a newly discovered protease mainly secreted by the liver. In the circulation, 
PCSK9 binds to LDLR on the surface of hepatocytes and leads to its degradation. Gain-of-function 
mutations in PCSK9 result in high plasma LDL cholesterol levels, whereas loss-of-function 
mutations cause increased numbers of LDL-receptor and are associated with reduced serum 
cholesterol (11). It is clear that the physiological function of PCSK9 is involved in LDL-receptor 
regulation. Mutations such as C679X that lead to no-functional PCSK9 in the body, not only reduce 
plasma cholesterol, but also are associated with a marked reduction in the incidence of coronary 
heart disease (10). All these findings have made PCSK9 an attractive target for cholesterol-lowering 
therapy for hypercholesterolemia. However, its role in lipid metabolism, especially in apoB, the most 
important lipoprotein in VLDL and LDL particles, remains controversial. 
The purpose of the current study was to investigate the effects of PCSK9 on apoB and the 
mechanism by which PCSK9 regulates apoB and apoB-containing lipoproteins. This investigation 
will bring forth a better understanding of the physiological function of PCSK9 and its role in lipid 
metabolism. We hypothesized that overexpression of PCSK9 would lead to an increased plasma 
apoB containing lipoprotein levels as well as an increased apoB synthesis rate, irrespective of the 
presence of LDLR. It is anticipated that the proposed studies will result in understanding the 
relationship of PCSK9 and apoB and provide new insights to the mechanism of how PCSK9 
regulates apoB. The study will provide evidence for the development of new cholesterol lowering 
therapeutic interventions.  
The specific aims of this project are: 
Specific Aim 1. To elucidate the effect of PCSK9 expression on lipoprotein and apoB 
metabolism.  
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We used a second-generation adenoviral vector to achieve a long-term (30 days) expression of 
PCSK9 in mice with or without the LDLR, including C57BL/6J, LDLR deficient mice of Ldlr-/-, and 
LDb (Ldlr-/-Apobec1-/-) mice. The second-generation adenoviral vector provides long-term gene 
expression with low toxicity, which is critical to the study on the effects of the overexpression on 
lipoprotein metabolism. 
Specific Aim 2. To delineate whether PCSK9 would interact with apoB. 
Wild-type PCSK9 and its gain-of-function mutations increase apoB containing lipoprotein secretion 
(27, 93). We hypothesized that PCSK9 would interact with apoB, resulting in overproduction of 
apoB. We used in vitro and in vivo assays to demonstrate the physical interaction of PCSK9 and 
apoB intracellularly. 
Specific Aim 3. To investigate the impact of PCSK9 on apoB production.  
ApoB is constitutively expressed in the hepatocytes. Most of the apoB is probably degraded via 
autophagosome/lysosomal pathway. We hypothesized that PCSK9 would regulate apoB production 
by altering the degradation pathway of apoB. We demonstrated the significant impact of the 
regulation of PCSK9 on apoB production in a LDLR independent fashion. 
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MATERIALS AND METHODS 
1. Animal studies 
C57BL/6, Pcsk9-/- and Ldlr-/- mice were purchased from Jackson Laboratory (Bar Harbor, 
ME). LDb (Ldlr-/-Apobec1-/-) mice were generated in Teng’s laboratory as described previously 
(18-20). Ldlr-/- Apobec1-/-Pcsk9-/-LDb triple knockout mice were generated by crossing Pcsk9-/- 
with LDb mice, and confirmed genotype by PCR. The sequencing primers are:  
Ldlr forward: 5′-ACC CCA AGA CGT GCT CCC AGG ATG A  
Ldlr reverse: CGG AGT GCT CCT CAT CTG ACT TGT.  
Apobec1 forward: 5′-TGA GTG AGT GGT GGT GGT AAA  
Apobec1 reverse: CGA AAT TCC TCC AGC AGT AAC.  
Pcsk9 forward: 5′-ATT GTT GGA GGG AGA AGT ACA GGG GT  
Pcsk9 reverse: 5′-GGG CGA GCA TCA GCT CTT CAT AAT CT.  
Neo forward: 5′-ATT GTT GGA GGG AGA AGT ACA GGG GT  
Neo reverse: 5′-GAT TGGGAA GAC AAT AGC AGG CAT GC.  
Mice were kept in a barrier facility with a 12:12 h dark–light cycle and maintained on a 
standard laboratory chow diet. All the animal experiments were conducted in accordance with the 
Guidelines of the Animal Protocol Review Committee of the University of Texas Health Science 
Center at Houston.  
 
2. Cell lines used for this study 
Stably expressing human apo-18,-48, and -100 McArdle RH-7777 (McA-RH7777) cell lines: 
These 3 stable cell lines were obtained from Dr. Zemin Yao’s laboratory at University of Ottawa, 
Ottawa, Canada. These cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum, 100 Units/mL penicillin G sodium, 100 g/mL 
streptomycin sulfate, and 200 g/mL G418. 
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HepG2 cells (human hepatocellular carcinoma): The cells were cultured in MEM supplemented 
with 10% fetal bovine serum, 100 Units/mL penicillin G sodium, 100 µg/mL streptomycin sulfate, 
1X non-essential amino acid, and 1X sodium pyruvate.  
HepG2 cell line stably expressing Apobec1: This stable cell line expressing the rat Apobec1 was 
generated in Teng’s laboratory. The cells were cultured in MEM supplemented with 10% fetal 
bovine serum, 100 Units/mL penicillin G sodium, 100 µg/mL streptomycin sulfate, 1X non-essential 
amino acid, 1X sodium pyruvate, and 200 µg/mL G418. 
COS1 cells (African green monkey kidney fibroblast-like cell line): These cells were maintained in 
DMEM supplemented with 10% fetal bovine serum, 100 Units/mL penicillin G sodium, and 100 
µg/mL streptomycin sulfates. 
HEK293 cells (human embryonic kidney cell line): These cells were maintained in high glucose 
DMEM supplemented with 10% fetal bovine serum, 100 units/mL penicillin G sodium, and 100 
µg/mL streptomycin sulfate. 
E.C7 cells (HEK293 cell stably expressing adenoviral DNA polymerase, (94)) The cell line was 
obtained from Etubics Co. (Seattle, WA). These cells were maintained in DMEM supplemented with 
10% fetal bovine serum, 100 units/mL penicillin G sodium, and 100 µ/mL streptomycin sulfate. 
 All cell lines were maintained at 37°C in a humidified incubator containing 5% CO2.  
 
3. Plasmid vectors constructed for this study:  
pcDNA3-hPCSK9: Full-length human PCSK9 (NM_174936) with a FLAG tag in EcoRI and XhoI 
site of pcDNA3 vector were obtained from Dr. Jay D Horton at University of Texas Southwestern 
Medical Center. 
pcDNA3-mPcsk9: Full-length mouse PCSK9 (NM_153565) with a FLAG tag were PCR amplified 
from pcDNA3-mPcsk9 (provided by Dr. Jan L Breslow from Rockefeller University) and cloned 
into EcoRI and XhoI site of pcDNA3 vector. The primer sequences are -Forward: 5′-CCA GTG TGC 
TGG AAT TCG CCA CCA TGG GCA CCC ACT GCT CTG CG, and Reverse: 5′-CCC CTC GAG 
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TCA CTC ACT TGT CAT CGT CGT CCT TGT AGT CCT GAA CCC AGG AGG CCT TTG CTG 
AAG G. 
 pcDNA3-LDLR-FLAG: Full-length mouse LDLR (NM_001252658) with a FLAG tag were 
amplified by PCR with primers − Forward: 5′-AGT GAA GCT TGA ATT CGC CAC CAT GGG 
GCC CTG GGG CTG GAA A and Reverse: 5′-CCC TCT AGA TCA CTC ACT TGT CAT CGT 
CGT CCT TGT AGT CCT GGA GCG CCA CGT CAT CCT CCA GAC TGA C−, and cloned into 
HindIII and XbaI site of pcDNA3 vector. 
pVP-16-PCSK9: Full-length human PCSK9 cDNA was cloned into pVP-16 vector of EcoRI and 
XbaI sites, which generated a fusion protein of the VP-16 activation domain and PCSK9 as pVP16-
PCSK9.  
pM-apoB18: pCMV-apo18 was obtained from Dr. Zemin Yao’s laboratory at University of Ottawa, 
Ottawa, Canada. We designed primers−forward: 5′-TAT GAA TCC ATG GAC CCG CCG AGG 
CCC and reverse: 5′-TAT GGA TCC CTA GAT CCC CTG CAG AGT−flanking the apoB-18 
cDNA (NM_000384, nucleotides 129-2555) of pCMV-apoB-18 to amplify the apoB18 DNA. The 
amplified fragment was sequenced and cloned into EcoRI and BamHI sites of pM vector. This 
recombinant vector produced a fusion protein of GAL4-binding domain and apoB18 as pM-apoB-18.  
pM-Apobec1: This vector was previously cloned by Teng’s laboratory (95). The full-length rat 
Apobec1 (NM_001134391) was cloned into EcoRI and BamHI site of pM vector and generated a 
fusion protein of GAL4-binding domain and Apobec1. 
pM-LDLR: Full length human LDLR (NM_001252658) were digested from pCMV-hLDLR 
(provided by Dr. Kazu Oka from Baylor College of Medicine) by Ecl360II (blunted) and XbaI sites, 
and subcloned into SmaI and XbaI site of pM vector and generated a fusion protein of GAL4-binding 
domain and LDLR. 
All plasmid vectors were sequenced by commercial sequencing company from both 
directions and the sequences were confirmed with NCBI public sequences.  
 
23 
 
4. Cell transfection assay used in this study: 
We used lipofectamine2000 (Invitrogen) to perform plasmid DNA transfection assay into 
cells. Briefly, cells were seeded onto a 12-well plate at 70–80% confluence in antibiotic-free media. 
The next day, 1 μg of each plasmid DNA was prepared in 200 ul serum free medium with 4 µg 
lipofectamine-2000. After 20 min incubation at room temperature, the mixture was added into each 
well, which had been changed with 1 mL fresh antibiotic-free medium. The cells were incubated 
with the plasmid DNA for 6 h at 37°C, 5% CO2, followed by addition of 2 mL fresh complete media. 
At 48 h after transfection, the cells were lysed with 1X RIPA lysis buffer (Radioimmunoprecipitation 
assay buffer from Cell Signaling, Danvers, MA. It contains 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% Na-deoxycholate, 2.5 mM Na-pyrophosphate, 1 mM 
beta-glycerophosphate, 1 mM Na3VO4, 1 g/mL leupeptin) and both cell lysates and media were 
collected for the analysis of protein expression. 
 
 
5. Construction and Production of E1-, E2b-, E3-deleted second-generation adenovirus 
type 5 vector expressing hPCSK9 
We chose to use the E1, E2b, and E3 genes deleted adenovirus vector to express PCSK9 for 
this study since this adenoviral vector has been shown to have low toxicity with long-term 
expression (94). The E1-, E2b-, E3-deleted adenovirus type 5-vector pAd-del-pol, adenoviral-CMV 
shuttle vector pD2007MCS, and E.C7 cell line were obtained from Etubics Corporation (Seattle, 
WA). The full-length hPCSK9 cDNA with a FLAG tag and a plasmid vector of pcDNA3-PCSK9-
D374Y mutant were obtained from Dr. Jay D Horton, University of Texas Southwestern Medical 
Center (16). 
Due to an original design defect that both the pD2007MCS shuttle vector and the pAd-del-
pol adenoviral vector contain the same Amp resistance gene, which results in difficulties in the 
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cloning selection, we had to use the following modified strategy to construct the adenoviral vector. 
As shown in the flow chart of Figure M-1, we cloned the PCSK9-FLAG cDNA into HindIII/EcoRV 
sites of pAdEasy shuttle vector driven by CMV promoter (Invitrogen, CA). This pAd-Easy vector is 
Kanamycin resistant. This pAd-Easy-PCSK9-Kan shuttle vector was, then, co-transformed with 
pAd-del-pol-Amp vector into BJ5183 competent cells to generate the pAd-PCSK9-Kan (this is a 2nd 
generation adenoviral vector). However, the pAd-del-pol vector has an internal PacI site, which 
prohibits us to use the PacI site to linearize the pAd-PCSK9-Kan, so we had to do the second 
recombination to recombine the pAd-PCSK9-Kan with pD2007MCS-PCSK9 in BJ5183 competent 
cells to generate the pD2007MCS-PCSK9-Amp. This homologous recombination was selected by 
Amp. After 2 cloning (pD2007-CMV-PCSK9 and pAd-Easy-PCSK9) and 2 recombination 
procedures, we generated a pAd-D2007-CMV-PCSK9-Amp vector ready for the production of 
adenovirus. 
We linearized the pAd-D2007-CMV-PCSK9-Amp vector with FseI site and transfected this 
recombinant vector into E.C7 cells to produce the recombinant adenovirus (Ad-PCSK9). The crude 
virus was purified by using 2 rounds of CsCl2 density gradient ultracentrifugation. Briefly, NVT65 
centrifuging tubes were preloaded with 3 mL of 1.25 g/mL CsCl solution (top) and 3 mL 1.5 g/mL 
CsCl solution (bottom). The crude virus lysates (~5 mL) were loaded onto the top of 1.25 g/mL CsCl 
solution and subjected to ultracentrifuge at 35,000 rpm in NVT65 rotor for 3 h. We collected a high-
density band by using a 21G needle between the layers of 1.25 g/mL CsCl solution and the 1.5 g/mL 
CsCl solution. The collected band was loaded onto 7 mL of 1.34 g/mL CsCl solution and 
ultracentrifuged again under the same conditions. Purified virus bands were dialyzed against 4 L of 
0.01 M Tris pH 8.0 containing 1% glycerol overnight. We used qPCR to quantify the titer of Ad-
PCSK9 virus (usually 1012–1013 viral particles/mL). The primers and probe sequences targeting at 
CMV promoter for the qPCR are as follows: 
Forward: 5′- ATA CGT CAT TAT TGA CGT CAA TG;  
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Reverse: 5′- CGT TAC ATA ACT TAC GGT AAA TG; 
Probe: 5′- 6-FAM/CCT GGC TGA CCG CCC AAC GAC.  
A control adenovirus, referred as Ad-Null, was constructed the same way without the cDNA 
insert. We also constructed and produced the adenoviral vector expressed mouse PCSK9, termed Ad-
mPcsk9.   
To confirm the expression of recombinant PCSK9 protein by Ad-mPcsk9 and Ad-hPCSK9, 
we infected the 293 cells with the adenoviral vectors (Ad-Null, Ad-mPcsk9, and Ad-hPCSK9). At 48 
h after infection, cell lysates and cell media were collected, followed by SDS-7.5% PAGE gel 
electrophoresis. The proteins were transferred to PVDF membrane and hybridized with anti-Flag 
antibody (Sigma). We also transfected 293 cells with pcDNA3-PCSK9 vector, and the protein 
expressed by this transfection method was used as a PCSK9 marker. As shown in Figure M-2, both 
the pre (74kDa) and mature (63 kDa) forms of PCSK9 were expressed by Ad-mPcsk9 and Ad-
PCSK9. Notice, most of the proteins expressed are mature PCSK9 in both cell lysates and cell 
media.   
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 PC
by 
pA
a 2
the
pD
rec
pro
pro
 
 
pAd
PCS
ure M-1. Co
SK9-FLAG 
CMV promo
d-del-pol-Am
nd generation
 pAd-PCSK
2007MCS-PC
ombination p
duction of ad
duce the reco
Easy- 
K9-Kan 
nstruction o
cDNA was c
ter. This pA
p vector into
 adenoviral 
9-Kan with p
SK9-Amp. 
rocedures, p
enovirus. Th
mbinant ade
Co-t
BJ5
f E2b-Ad-PC
loned into H
d-Easy-PCSK
 BJ5183 com
vector). The 
D2007MCS
 This homolo
Ad-D2007-C
e vector was
novirus (E2b
26 
FseI-L
ransform in
183 bacteria
SK9. 
indIII/EcoRV
9-Kan shut
petent cells 
second recom
-PCSK9 in B
gous recomb
MV-PCSK9-
 linearized w
-Ad-PCSK9)
inearized ∆
transf
to 
 
 sites of pA
tle vector wa
to generate t
bination wa
J5183 comp
ination was 
Amp vector
ith FseI and t
.   
E2bAd-P
ected into
dEasy shuttl
s then co-tra
he pAd-PCS
s performed b
etent cells 
selected by A
was generate
ransfected in
CSK9 was
  
e vector driv
nsformed w
K9-Kan (this
y recombini
to generate t
mp. After tw
d ready for t
to E.C7 cells
 
en 
ith 
 is 
ng 
he 
o 
he 
 to 
27 
 
 
HEK293 cells 
pC
D
N
A
3-
PC
SK
9 
co
nt
ro
l 
A
d-
N
ul
l 
A
d-
m
Pc
sk
9 
A
d-
hP
C
SK
9 
co
nt
ro
l 
A
d-
N
ul
l 
A
d-
m
Pc
sk
9 
A
d-
hP
C
SK
9 
Cell media Cell lysates 
Figure M-2. Western blot analysis of PCSK9 in HEK-293 cells infected with Ad-PCSK9. 
The 293 cells were infected with Ad-PCSK9 or Ad-Null. Cell lysates and cell media were 
subjected to SDS/PAGE, followed by Western blot analysis using anti-FLAG antibody. The 
position of PCSK9 is marked. The upper bands are the pre-form of PCSK or Pcsk9, and the 
lower bands are the mature form of PCSK9 or Pcsk9. 
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6. Transduction of Ad-PCSK9 and Ad-Null into mice 
Male C57BL/6J, Ldlr-/-, and LDb mice (n = 24 for each group) at 2 months of age were 
transduced with Ad-PCSK9 or Ad-Null virus (1×1010 viral particles/mouse) via tail vein injection. 
Fasting (~16 h) blood samples were collected prior to (day 0) and post adenovirus injection at days 
7, 14, 21, and 30, respectively. We collected blood (250 µL) via retro-orbital plexus using heparin 
coated capillary tubes (Fisher Scientific) under general anesthesia with 1.25% Avertin. At the end of 
the indicated time, each animal was anesthetized, sacrificed, and perfused using 20 mL ice-cold PBS. 
The tissue samples were collected, snap frozen in liquid nitrogen, or embedded in OCT. The samples 
were stored at –80°C until analysis. 
 
7. Separation of plasma lipoproteins by Fast Protein Liquid Chromatography  
We used Fast Protein Liquid Chromatography (FPLC) with 2 continuous Superose 6 
columns (GE, Piscataway, NJ) to separate lipoprotein particles from mouse plasma. In general, 
pooled mouse plasma (225 μ) was separated by FPLC into VLDL, LDL, and HDL particles. 
Fractions (0.5 mL each, total 40 fractions) were eluted using 150 mM NaCl, 1 mM EDTA, and 
0.02% NaN3 pH 8.2 (20, 42). Each fraction was analyzed for the levels of cholesterol, triglyceride, 
and apolipoproteins. 
 
8. Measurement of lipids values in plasma and plasma lipoprotein fractions 
Cholesterol and TAG concentrations in either plasma or each FPLC fraction were 
determined using the Cholesterol E and the L-Type Triglyceride M kits (Wako Chemicals, 
Richmond, VA), respectively. 
 
9. Western blot analysis  
Plasma and lipoprotein fractions from plasma:  
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Mouse plasma samples (3 µL from C57BL/6J, 1 µL from Ldlr-/- or LDb) or FPLC fractions 
(10 µL/fraction) were resolved by SDS-PAGE. We used 6% ProSieve-50 gel (FMC BioProducts, 
Rockland, ME) to separate apoB100 and apoB48 proteins. We used SDS-7.5%PAGE to separate 
PCSK9, and SDS-12.5%PAGE to separate apoE and apoA-I. The proteins were transferred onto 
PVDF membrane (Millipore). The antibodies used for the analysis of apolipoproteins are as follows: 
Anti-mouse apoB (1:10,000 dilution, Abcam, Cambridge, MA) was used to detect mouse apoB-100 
and apoB-48. 
Monoclonal antibody 1D1 (Heart Institute, University of Ottawa, Ottawa, Canada) was used to 
detect human apoB. 
Anti-mouse apoE (1:5,000 dilution) and anti-mouse apoA-I (1:10,000 dilution) were obtained from 
Dr. B Ishida, University of San Francisco to detect mouse apoE and mouse apoAI, respectively. 
Anti-FLAG antibody (1:5,000 dilution, Sigma) was used to detect the expressed recombinant 
PCSK9 containing the FLAG tag.  
 
10. Liver Proteins from Liver homogenates 
The frozen liver samples (~100 mg) were homogenized in 1X RIPA lysis buffer containing 
complete protease inhibitor cocktail (Roche Mannheim, Germany). The homogenates were 
centrifuged at 13,000 rpm for 10 min and the supernatants were subjected to protein concentration 
determination by Bradford assay. To analyze the liver proteins, we used 50 µg of total protein to be 
separated by SDS-PAGE; 
SDS-6% PAGE for FAS (fatty acid synthetase); SDS-7.5% PAGE for SREBP-1a, -1c, -2 
(Sterol Regulatory Element-Binding Protein); SDS-7.5% PAGE for HMG-CR (3-hydroxy-3-methyl-
glutaryl-CoA reductase); and SDS-10% PAGE for SCD1 (stearoyl-CoA desaturase-1). The 
antibodies used to detect these proteins are as follows: 
Anti-Srebp1 (1:2,000, Abcam), anti-Srebp2 (1:2,000, Cayman Chemical, Ann Arbor, MI), anti-FAS 
(1:2,000, Abcam), anti-SCD1 (1:2,000, Abcam), and anti-HMGCR (1: 2,000, Santa Cruz). 
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In general, after the proteins were transferred to PVDF membrane, the membrane was 
incubated with the primary antibodies at 4°C overnight. On the next day, the membrane was washed 
and blotted with secondary antibodies such as Alexa-680 conjugated anti-rabbit secondary antibody 
(1:10,000) at RT for 1 h. The membrane was washed and scanned using Odyssey Infrared Imaging 
system (Li-COR, Lincoln, NE). The intensities of protein bands were semi-quantified using the 
software of the Li-COR system. 
 
11. Real-time Quantitative PCR 
Total RNA was extracted from mouse livers by using the Qiazol RNA extraction reagent 
(Qiagen, Valencia, CA). The concentrations of the RNAs were determined by using Nanodrop 2000 
(Thermo Scientific). Two micrograms of total RNA were digested with DNase I (Ambion, Austin, 
TX) to remove any trace of genomic DNA. The DNAse I treated RNA was transcribed into cDNA 
using Achieve Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Real-time 
quantitative PCR (qPCR) was performed on ABI Prism 7900-HT Sequence Detection System 
(Applied Biosystems). 
We used both SYBR Green (SYBR Green PCR Master Mix, Bio-Rad) and TaqMan assays 
(Applied biosystem) to quantify gene expression levels. For SYBR Green assay, each primer set was 
optimized to eliminate primer-dimer formation. The following 10 genes were determined using 
SYBR Green standard curve qPCR assay: HMG-CoA synthetase, HMG-CoA reductase, acetyl-CoA 
carboxylase, fatty acid synthase, stearoyl-CoA desaturase-1, glycerol-3-phosphate acyltransferase, 
diacylglycerol acyltransferase-1, SREBP1-a, –c, and 2. The gene expression levels were normalized 
with mouse 16S RNA. 
The mouse apoB RNA levels were quantified using the TaqMan primer/probe standard 
curve assay. The mouse apoB RNA levels were normalized with 18S RNA. Sequences of primers 
and probes used in this study are listed in Table 1. 
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Table 1. Primer sequences and optimized primer concentrations used for SYBR real-time 
quantitative PCR. All the primers and probes were designed by using Primer Express software 
(Applied Biosystems Inc.) 
 
F = forward primer; R = reverse primer 
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Gene 
Symbol 
Access 
number 
Primer and probe sequence Optimized 
concentrat
-ion (μM) 
Srebp-1a NM_011480 F: 5' CGGCTCTGGAACAGACACTG 2 
  R: 5' GAAGTCACTGTCTTGGTTGTTG 2 
Srebp1-c NM_011480 F: 5' ATCGGCGCGGAAGCTGTCGGGGTAGCG 2 
  R: 5' GAAGTCACTGTCTTGGTTGTTG 2 
Srebp2 NM_033218  F: 5' GTTCTGGAGACCATGGAG 5 
  R: 5' AAACAAATCAGGGAACTCTC 5 
HMGCoA 
reductase 
NM_008255 F: 5' CTTTCAGAAACGAACTGTAGCTCAC 2 
  R: 5' CTAGTGGAAGATGAATGGACATGAT 2 
HMGCoA 
synthase 
NM_145942 F: 5' CAGCCATTTGTTACAGCTTATTCTC 2 
  R: 5' 
TCTTTTTAATTGCCACATATTATTTTAGAA 
2 
Fas NM_007988 F: 5' AGCACTGCCTTCGGTTCAGTC 2 
  R: 5' AAGAGCTGTGGAGGCCACTTG 2 
Scd1 NM_009127   F: 5' CTGCAGGTTGTGCTAGATGGGATGG 2 
  R: 5' GCCTGGGGTCTTTGGTAAGTAGGC 2 
Acc NM_133904   F: 5' TTATCTCTGGAGAACCTCTCTAATGG 2 
  R: 5' AGACACTTAGCAAGAGCAAAAATGA 2 
Gpat NM_008149  F: 5' CCTCTCAGTGGTAGTGGATACTCTGT 1 
  R: 5' GTGACCTTCGATTATGCGATCAT 1 
Dgat1 NM_012079 F: 5' GGCATTCACAGCAATGATGGC 2 
  R: 5' CCACACAGCTGCATTGCCATA 2 
m16S XM_003085
753  
F: 5' AGGAGCGATTTGCTGGTGTGG 0.5 
  R: 5' GCTACCAGGGCCTTTGAGATG 0.5 
mApoB NM_009693 F: 5' ATGTACTAATTGCCATAGATAGTGCCA 0.25 
  R: 5' TCGCGTATGTCTCAAGTTGAGAG 0.25 
  Probe: 6FAM-ATCAACTTCAATGAAAAA-
MGBNFQ 
0.12 
18S X00686 F: 5' TAACGAACGAGACTCTGGCAT 0.17 
  R: 5' CGGACATCTAAGGGCATCACAG 0.17 
  Probe: 6FAM-
TGGCTGAACGCCACTTGTCCCTCTAA-
TAMRA 
0.11 
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12. Pulse-chase experiment of apoB biosynthesis in mouse primary hepatocytes 
Mouse primary hepatocytes were isolated using a modified procedure established by David 
Moore’s laboratory (43) from Baylor College of Medicine, Houston, TX.   Mice (C57BL/6J, Ldlr-/-, 
and LDb) were anesthetized, the livers were first perfused with 50 mL HBSS (Invitrogen) containing 
0.5 mM EGTA at a rate of 3 mL/min via the portal vein, followed by 50 mL EBSS (Invitrogen) 
containing 0.3 mg/mL liberase blendzyme (Roche) and 0.04 mg/mL trypsin inhibitor (Invitrogen) at 
37°C. After perfusion, the liver was removed, the hepatic capsule was peeled off, and hepatocytes 
were dispersed by shaking the digested liver in a pre-warmed William’s E medium (Invitrogen) at 
37°C. The hepatocytes were filtered through a 100-µm nylon cell strainer (BD Falcon, Franklin 
Lakes, NJ), the cells were washed twice with William’s E medium, and re-suspended in 20 mL 
William’s E medium. The hepatocytes were then loaded onto a 50 mL falcon tube containing a 
discontinuous Percoll gradient solution (Invitrogen) (from top to bottom: 5 mL 1.06 g/mL, 7 mL 
1.08 g/mL, 5 mL 1.12 g/mL). After centrifugation at 700 g for 20 min, the cells were collected from 
the layer between 1.08 and 1.12 g/mL. The cells were washed twice with 20 mL William’s E 
Medium, and re-suspended in hepatocyte culture medium (William’s E Medium supplemented with 
10% fetal bovine serum, 100 units/mL penicillin G sodium, 100 µg/mL streptomycin sulfate, and 1X 
insulin-transferrin-selenium solution (Invitrogen)). The viability of cells (90–95%) was determined 
using trypan blue dye exclusion. 
The cells were plated (0.5 × 106 cells/well) onto a 6-well plate pre-coated with 1 mg/mL 
mouse type IV collagen, incubated for 6 h, followed by infection overnight with Ad-Null or Ad-
PCSK9 (multiplicity of infection, MOI = 50:1). On the next day, the media were changed to 
Met/Cys-free DMEM for 30 min prior to pulse labeling. The cells were pulsed with 100 µCi/mL 
[35S] Methionine/Cysteine (Perkin Elmer, Waltham, MA) in Met/Cys-free DMEM for 15 min, 
followed by chasing with serum-free DMEM containing 2 mM Met for 30, 60, 120, 180, and 240 
min. At the indicated time point, media were collected, and cells were lysed with 100 µL RIPA 
buffer (Cell Signaling) containing a protease inhibitor cocktail (Roche).  
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The media (400 µL) and cell lysates (50 µL) were incubated with 10 µL anti-mouse apoB 
(Abcam) or anti-albumin (GenWay Biotech, San Diego, CA) antibodies in 500 µL 1X RIPA buffer 
containing protein-A-agarose beads (Roche) at 4°C for 1 h with rotation to immunoprecipitate the 
apoB or albumin. The immunoprecipitates were washed with 500 µL 1X RIPA buffer for 5 times 
and then eluted with SDS sample loading buffer and subjected to gel electrophoresis (6% Prosieve 
gel for apoB and SDS-10% PAGE for albumin). The gels were fixed and amplified in 1 M sodium 
salicylate (Sigma-Aldrich) for 15 min, dried, and scanned by a PhosphoImage system (Bio-Rad). 
The bands were quantified using QuantityOne software (Bio-Rad). The results are expressed as total 
radioactivity of each band. 
 
13. ELISA to measure mouse and human PCSK9 
Mouse PCSK9:            
We used Mouse/Rat PCSK9 ELISA kit (Circulex Bio, Ltd.) to determine the PCSK9 levels 
in mouse plasma and FPLC fractions separated from mouse plasma. Briefly, diluted samples (1:100 
C57BL/6 serum, 1:1000 for Ldlr-/- and LDb, 1:20 for FPLC fractions) and PCSK9 standards 
(provided by the kit) were incubated in the 96-well plate at room temperature for 1 h with horizontal 
shaking. After washing 4 times with washing buffer, 100 µL HRP conjugated detection antibody 
were added to each well and incubated at RT for 1 h with horizontal shaking. Each well was then 
washed 4 times with washing buffer, followed by addition of 100 µL substrate reagents onto each 
well and incubated at RT for 10 min. The color reactions were stopped by adding 100 µL stopping 
solutions. The absorbance was measured at 450 nm wavelength and the results were analyzed by 4-
parameter evaluation method on Tecan infinite m200 microplate reader (TECAN, San Jose, CA).  
Human PCSK9: 
We used human PCSK9 ELISA kit (R&D, Ltd.) to determine the recombinant human 
PCSK9 expressed by Ad-PCSK9 in mouse plasma and FPLC fractionations separated from mouse 
plasma. Briefly, diluted samples such as Ad-PCSK9 transduced mouse plasma (1:100,000), FPLC 
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fractions (1:1,000), and PCSK9 standards (provided in the kit) were incubated in the ELISA wells at 
room temperature for 2 h. After washing 4 times with washing buffer, 100 µL HRP conjugated 
detection antibody were added to each well and incubated at RT for 2 h. Each well was then washed 
4 times with washing buffer, followed by addition of 100 µL substrate reagents onto each well and 
incubated at RT for 30 min. The color reactions were stopped by adding 50 µL stopping solutions. 
The absorbance was measured at 450 nm wavelength and the readings were analyzed by 4-parameter 
evaluation method on Tecan infinite m200 microplate reader (TECAN).  
 
14. Co-immunoprecipitation of PCSK9 and apoB 
McA-RH7777 cells stably expressing human apoB-18 or apoB-48 were maintained as 
described. The cells were plated onto a 6-well plate at density of 106 cells/well, and cultured for 18 h 
in DMEM containing 10% FBS and 200 µg/mL G418. The cells were infected with Ad-PCSK9-
FLAG or Ad-Null (MOI = 50:1). At 24 h after infection, the cells were washed with PBS twice and 
lysed with 100 µL 1X RIPA buffer. The cell lysates were centrifuged at 10,000 rpm for 10 min, the 
supernatants were collected and incubated with 50 µL anti-FLAG M2 agarose (Sigma-Aldrich) for 3 
h at 4°C to precipitate FLAG-tagged PCSK9. The immunocomplexes were washed 3 times with 500 
µL RIPA buffer, eluted with SDS sample-loading buffer by boiling them for 5 min. The mixtures 
were subjected to SDS-PAGE (6% Prosieve gel for apoB and 7.5% gel for PCSK9). After gel 
electrophoresis, the proteins were transferred to the PVDF membrane, the membrane was incubated 
with mAb 1D1 (1:5,000) to detect human apoB-18 and apoB-48, and anti-FLAG to detect PCSK9. 
 
15. Protein-Protein interaction: Mammalian matchmaker Two-hybrid System 
We used a mammalian matchmaker two-hybrid system (Clontech, Mountain View, CA) to 
examine the protein–protein interaction. The plasmid vectors used for this assay were described 
above. 
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Three plasmid vectors: pM-apoB-18 (0.5 µg), pVP-16-PCSK9 (0.5 µg), and pG5-SEAP (0.5 
µg) were co-transfected into either 293 cells or COS-1 cells using lipofectamine 2000 (Invitrogen). 
At the end of the experiment (48 h after transfection), the interaction between these 2 proteins was 
detected by measuring SEAP activities in the cell media using Great EscAPe SEAP 
Chemiluminescence Detection Kit (Clontech). The Light Unit was determined using Tecan infinite 
m200 chemiluminescent reader (TECAN, San Jose, CA). The negative controls of pM and pVP16 or 
pM-Apobec1 and pVP16-PCSK9 with the pG5-SEAP; and the positive controls of pM-LDLR, pVP-
16-PCSK9, and pG5-SEAP were performed simultaneously. The results were expressed as light 
units.   
 
16.  Duolink in situ proximity ligation assays (PLA) and Immunofluorescence analysis 
Duolink in situ proximity ligation assays (PLA): 
We used in situ PLA assay kit obtained from OLINK Bioscience (Uppsala, Sweden) to study 
the endogenous protein–protein interaction. The primary antibodies used for this assay were 
monoclonal antibody PCSK9 (mC33-Mab1), anti-ApoB (Abcam), anti-Apobec1 (provided by Dr. 
Lawrence Chan’s laboratory from Baylor College of Medicine), and anti-LDLR (Cayman). HepG2 
cells or HepG2 cell line stably expressing Apobec1 were seeded onto a chamber slide (NUNC, 
Naperville, IL) at 104 cells/well and cultured overnight at 37°C, 5% CO2. On the next day, the cells 
were washed with ice-cold PBS, fixed in 4% paraformaldehyde at RT for 10 min, followed by 
permeabilization with PBS containing 0.25% Triton X-100 for 10 min. The cells were blocked with 
blocking buffer (PBS containing 1% BSA) for 1 h at RT, followed by incubation with primary 
antibody (1:100 dilution in blocking buffer) at 4°C overnight. Note, to study the interaction between 
LDL receptor and PCSK9, we did not permeabilize the cells since permeabilization would poke 
holes in the cell membrane and change the confirmation of the protein.  
We followed the instruction of in situ PLA commercial kit to detect protein–protein 
interaction. Briefly, after primary antibodies incubation the cells were washed with PBS, followed by 
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incubation with PLA secondary probes (1:5 dilution in blocking solution; anti-rabbit/PLUS and anti-
mouse/MINUS PLA probes) for 1 h at 37°C. The slide was washed 2 times with Wash Buffer-A, 5 
min each time. The cells were then incubated with 1:40 diluted Ligase for 30 min at 37°C in a pre-
heated humidity chamber for ligation. After the ligation step, the slides were washed 2 times with 
Wash Buffer-A, 2 min each. The slides were then incubated with 40 µL diluted polymerase (5 units, 
1:80 dilution) for 100 min at 37°C in a pre-heated humidity chamber to amplify the signal. At the 
end of the reaction, the slides were washed quickly with Wash Buffer-B to remove all the 
ingredients, followed by 10 min wash with Wash Buffer-B again 2 times, and finally rinsed with 
1:100 diluted Wash Buffer-B for 1 min. The slides were dried at room temperature in the dark, and 
then mounted with Duolink II mounting medium containing DAPI. We examined the slides by using 
a Zeiss Axio Observer.D1m fluorescence microscopy with DAPI, FITC, and Texas Red filters. 
Control slides without primary or secondary antibodies were performed at the same time. 
Immunofluorescence analysis: 
 Before the in situ PLA assay, we performed immunofluorescence analysis by using each 
antibody to confirm the specificities of the antibodies. Briefly, after the cells were incubated with a 
single antibody overnight, followed by fixing and permeabilization, the cells were washed with PBS 
and incubated with fluorescence dye conjugated-secondary antibodies at 1:300 for 1 h at room 
temperature. After washing off the secondary antibody, the slides were incubated with DRAQ5 
nuclear staining reagent (Abcam) at 1:1,000 in PBS for 2 h at room temperature. The slides were 
mounted and examined using a Leica DM 600B confocal microscope with 488 nm, 594 nm, and 633 
nm filters.   
 
17. Autophagosome isolation 
We isolated autophagosomes from cells or mouse liver using the method described by 
Stromhaug et al. (46). Briefly, we used glass tissue grinder type B (Kimble Chase) to homogenize 
the McA-RH7777 cells or mouse livers from C57BL/6 or Ldlr-/- or LDb, or Pcsk9-/- or LDb/Pcsk9-
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/- in a homogenization buffer (HB, 0.25 M sucrose, 10 mM Hepes, 1 mM EDTA, 0.5 mM glycyl-l-
phenylalanine 2-naphthylamide (GPN), 1% DMSO, pH 7.3, ρ = 1.030 g/mL). After 6 min incubation 
at 37°C, the homogenate was centrifuged at 2,000 g for 2 min to separate nuclear pellet from 
supernatant. The supernatants were layered on the top of a discontinuous Nycodenz gradient solution 
(4 mL -1.072 g/mL and 4 mL-1.127 g/mL). The Nycodenz gradient was centrifuged at 4°C for 1 h at 
141,000 g using NVT65 rotor (Bechman Coulter). The interface band (~1 mL), which contains the 
autophagosomes, was collected using a 21G needle. This band was diluted with 5 mL of HB and 
layered on top of the 2nd discontinuous gradient (4 mL 33% Percoll in HB and 5 mL 22.5% 
Nycodenz [1.127 g/mL] in HB). The gradients were centrifuged for 30 min at 72,000 g using NVT65 
rotor (Bechman Coulter). We collected the purified autophagosome band at the interface between 
Percoll and Nycodenz solution using a 21G needle. The autophagosomes were lysed in 1X RIPA 
buffer, and we then used 30 µg of the lysed autophagosomes for SDS-PAGE analysis (6% Prosieve 
gel for apoB; 12.5% gel for PCSK9 and LC3). The proteins were then transferred to Immbolion-FL 
membrane, and probed with antibodies of anti-mouse apoB (1:5,000 dilution), anti-PCSK9 (Cayman 
Chemical, 1:2,000 dilution), and anti-LC3 (Cell Signaling, at 1:3,000 dilution), followed by anti-
rabbit secondary antibody (1:10,000). The intensities of the protein bands were quantified using an 
Odyssey Infrared Imaging system (Li-COR).   
 
18. Statistics  
All the results were expressed as mean ± SD. All comparisons were performed using 
GraphPad Prism software (ver 5) unpaired student t-test with two-tailed p value, except the long term 
cholesterol, TAG, and liver gene expression levels in which one-way and 2-way ANOVA were used. 
A p value of <0.05 was considered to be statistically significant. 
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RESULTS 
1. The rationale of using the 3 animal models for this study. 
The mechanism of how PCSK9 negatively regulates LDLR to increase LDL cholesterol 
levels has been intensively studied; however, the impact of PCSK9 on apoB production remains 
controversial and poorly understood. Here, I am re-emphasizing the rationale for our hypothesis, and 
I will provide the rationale for using the animal models for this study. 
ApoB is the structural protein for LDL, which is removed from circulation via LDLR. Thus, 
the regulation of LDLR by PCSK9 might alter apoB levels. Clinically, increased apoB concentration 
is associated with coronary artery disease (96). Therefore, we proposed to investigate the relationship 
of PCSK9 and apoB. 
 The publication by Sun et al. showed that McA RH-7777 cells stably expressing PCSK9 
D374Y mutant increased secretion of apoB containing lipoproteins in this stable cell line (27). 
Similarly, the increase of apoB containing lipoproteins secretion is also observed in humans with 
D374Y or S127R variant of PCSK9 (27, 97). In mice, the effects of PCSK9 on apoB secretion were 
not consistent. In wild-type C57BL/6 or Ldlr-/- mice, over-expression of wild-type PCSK9 or the 
S127R mutant for 3 days has no significant increase in apoB synthesis or production (20, 98, 99). 
Unchanged plasma apoB levels were also observed in both C57BL/6 and Ldlr-/- mice overexpressing 
PCSK9 for 5–6 days (98, 99). On the other hand, overexpression of PCSK9 in Ldlr-/- mice for 7 
days resulted in an approximately 2-fold increase in LDL-cholesterol and apoB levels (20). Thus, the 
apparent discrepancy among these experiments does not provide conclusive evidence on whether 
PCSK9 plays a role in apoB production.  
Interestingly, Pcsk9 deficient mice (Pcsk9-/-) had decreased production of apoB-containing 
lipoproteins (19, 93). These studies suggested that PCSK9 plays a role in apoB production, probably 
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via LDLR protein expression. Taken together, we proposed to test the hypothesis that PCSK9 
regulates apoB production, and to investigate whether LDLR is a necessary component. 
We proposed to test our hypothesis in the following 3 mouse models: C57BL/6J, Ldlr-/-, and 
LDb (Ldlr-/-Apobec1-/-). C57BL/6J mice, which express both LDLR and PCSK9 proteins are wild-
type and used as control. Ldlr-/- mice, which lack Ldlr gene were purchased from the Jackson 
laboratory. The third mouse model is LDb mice. Our laboratory crossbred Ldlr-/- mice with 
Apobec1-/- mice to produce a double knockout mouse model (Ldlr-/-Apobec1-/-) (62). In contrast to 
wild-type mice or Ldlr-/- mice, the phenotype of the LDb mice closely mimics humans with 
hyperlipidemia characterized by the secretion of apoB-100-containing lipoproteins only, with 
increased plasma levels of VLDL and LDL cholesterol and decreased levels of HDL cholesterol. In 
addition, these LDb mice spontaneously develop severe atherosclerotic lesions, when fed on a 
normal chow diet. Thus, LDb mice are distinctly different from Ldlr-/- mice, despite both lacking the 
LDLR. The lipoprotein phenotypes of these 3 mouse models are shown in Figure 1. Wild-type 
C57BL/6 mice have minute amounts of VLDL and LDL particles, and they carry most of their 
cholesterol in HDL particles. In contrast, mice deficient of LDLR (Ldlr-/-) have slightly elevated 
LDL, but most of the cholesterol is still carried by HDL. Mice deficient of both LDLR and Apobec1 
genes (LDb; Ldlr-/-Apobec1-/-), have elevated VLDL and LDL levels with decreased HDL particles. 
This lipoprotein phenotype mimics humans with hyperlipidemia. Thus, LDb mice are a humanized 
hyperlipidemia mouse model.  
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Figure 1. The cholesterol levels of lipoprotein fractions in patients with hyperlipidemia, LDb 
mice, wild-type C57BL/6 mice, and Ldlr-/- mice.  
Plasma from patient, LDb, C57BL/6, and Ldlr-/- mice was subjected to FPLC fractionation. 
Cholesterol levels in each fraction were measured using a commercial kit.   
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2. Recombinant PCSK9 with or without a FLAG tag have the same effect on apoB production 
Here, we examined whether recombinant PCSK9 with or without a FLAG tag have the same 
effect on apoB production in cells. We transfected HepG2 and McA-RH7777 cells with either 
pcDNA3-PCSK9 or pcDNA3-PCSK9–FLAG, and, 48 h after transfection, we collected the cell 
media, subjected them (50 μL) to SDS-7.5%PAGE, followed by Western blot analysis. We included 
pcDNA3 vector as the control and pcDNA3-PCSK9–D374Y-FLAG as the positive control. As 
shown in Figure 2, cells overexpressed PCSK9, or PCSK9-Flag, or PCSK9-D374Y mutant had 
significantly increased apoB levels secreted into the media, when compared with cells transfected 
with pcDNA3 vector only. Importantly, there were no differences on apoB levels in the cell media 
between cells expressing recombinant PCSK9 with or without a FLAG tag. Transfection of McA-
RH7777 cells with pcDNA3-PCSK9–D374Y-Flag results in more than 2-fold increase of apoB 
protein.  This result was demonstrated by others as the consequence of a strong interaction of PCSK9 
D374Y mutant with LDLR (27). Taken together, our results show that the expression of PCSK9 with 
or without a FLAG tag yielded similar effects on apoB production in cells. 
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3. Recombinant PCSK9 mediated by Ad-PCSK9 is expressed vividly in C57BL/6J, Ldlr-/- and 
LDb mice. The recombinant PCSK9-FLAG protein is biologically active 
Since the FLAG tag has no obvious adverse effect on apoB secretion, we chose to express 
FLAG-tagged human PCSK9 protein (Ad-PCSK9) using an Adenovirus E2b-region (pol gene) 
deleted second-generation adenoviral vector that exhibits a long-term gene expression and lower 
toxicity (94, 100). Because of the designing defect of antibiotic selection in the original E2b-deleted 
adenovirus system, we had to perform one extra step of recombination to replace the antibiotic 
resistant gene as described in detail in the Methods. The same adenovirus vector without the insert 
was constructed and used as control (Ad-Null). 
We transduced C57BL/6J, Ldlr-/-, and LDb male mice at 2-months of age (n = 24/group) 
with Ad-PCSK9 and Ad-Null for this study. The plasma samples were collected at day 0 before 
treatment and days 7, 14, 21, and 30 after the adenovirus administration. As shown in Figure 3, the 
levels of human PCSK9 proteins were expressed vividly up to 30 days in the mouse liver of the 3-
mouse model studied. The levels of recombinant PCSK9 were ~400-fold above the baseline as 
determined by ELISA (Figure 4); C57BL/6 = 646±48 µg/mL, Ldlr-/- = 967±44 µg/mL, and LDb = 
944±66 µg/mL.   
To confirm the biological function of the recombinant PCSK9 expressed by adenovirus, we 
used Western blot analysis to determine the LDL receptor levels in C57BL/6 mice. As expected, the 
expression of PCSK9 in C57BL/6 mice markedly decreased the LDLR protein in the liver (Figure 3). 
This effect demonstrates that the recombinant PCSK9-FLAG protein expressed by Ad-PCSK9 is 
biologically active. 
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Figure 4. The levels of over-expressed human PCSK9 in mice treated with AdPCSK9.  
We used commercial ELISA method to measure the human PCSK9 levels in each mouse 
after treated with AdPCSK9.  Mouse plasma was diluted to 1:100.  The diluted plasma was  
incubated in a pre-coated well with PCSK9 antibody. Standard ELISA procedure was 
performed according to the commercial manual. The plasma PCSK levels are represented as 
mean ± SD (n = 5).   
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4. Recombinant PCSK9 expressed via Ad-PCSK9 is detected mostly in the liver.  
The next question we asked was the distribution of recombinant PCSK9 after Ad-PCSK9 
transduction. We used real-time quantitative PCR and ELISA to examine the tissue distributions of 
endogenous mouse PCSK9 and recombinant human PCSK9 via Ad-PCSK9. Tissues such as liver, 
spleen, kidney, small intestine, and heart from C57BL/6 mice at day 7 after transduction with either 
Ad-Null or Ad-PCSK9 were analyzed. As shown in Figure 5, most of the endogenous Pcsk9 mRNAs 
were expressed in the liver and a lesser amount was expressed in the kidney, small intestine, heart, 
and spleen. Endogenous mouse PCSK9 protein was also expressed mostly in the liver with some 
amount detected in the small intestine. These results were similar to the reports by others (101).  
Most of the recombinant human PCSK9 mediated by Ad-PCSK9 (>95%) was also detected 
in the liver with minute amounts detected in the spleen, small intestine, and heart as shown in the 
gene expression of PCSK9 by real-time quantitative PCR and protein expression determined by 
ELISA method specific for Human PCSK9. Thus, liver is the predominant site for Ad-PCSK9 
mediated gene expression. Our results agreed with others that adenoviral vector preferably targeted 
the liver, since adenoviral “CAR” receptor is expressed mainly in the liver (102). 
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5. Overexpression of PCSK9 increases plasma cholesterol and triacylglycerol levels in an 
LDLR-independent fashion.  
Overexpression of PCSK9 via Ad-PCSK9 resulted in highly significant increased levels of 
plasma cholesterol and TAG in all 3-mouse models (Figure 6). The effect of PCSK9 expression on 
plasma cholesterol and TAG was much greater in C57BL/6 mice than that in the LDLR-null mice 
(Ldlr-/- and LDb). In C57BL/6 mice, the levels of plasma cholesterol and TAG were increased to an 
average of 3.7-fold and 8.5-fold, respectively, upon PCSK9 expression as compared to Ad-Null. The 
increase in the levels of plasma cholesterol and TAG in Ldlr-/- mice were 1.7-fold and 3.4-fold, 
respectively, and 1.5-fold and 1.5-fold, respectively, in LDb mice upon PCSK9 expression. The 
smaller increase in plasma cholesterol and TAG levels upon PCSK9 expression in LDLR-null mice 
(i.e., Ldlr-/- and LDb) was due to elevated baseline levels of the lipids in these animals. It was also 
noted that the increase in plasma TAG was much greater than that observed in case of plasma 
cholesterol upon PCSK9 expression, suggesting the increased VLDL secretion. The present results 
showing the effects of PCSK9 expression on plasma lipid levels in C57BL/6 mice are in accord with 
previous observations. (98, 103-106) The effect of PCSK9 expression on plasma lipids in the LDLR-
null mouse models is in agreement with results reported by Benjannet et al. (103) showing increased 
plasma lipid levels in Ldlr-/- mice. 
We used both one-way and 2-way ANOVA to analyze the effects of overexpression PCSK9 
on plasma cholesterol and triglyceride levels in mice. The STAT software is used to conduct one-
way and 2-way analyses of variance ANOVA (http://www.stata.com/capabilities/anova-manova/). 
For each time point, one-way ANOVA was used to test for significant difference between the mean 
values of phenotypes (cholesterol and triacylglycerol) of the Ad-PCSK9 group and the control virus 
Ad-Null group. As shown in Figure 7 and Table 2, one-way ANOVA shows that there were no 
differences at day 0 before treatment among the animals grouped to Ad-PCSK9 or Ad-Null. There 
were significant differences at each time point after the treatment in cholesterol and triglyceride 
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levels between Ad-Null and Ad-PCSK9 groups. Furthermore, the treatment resulted in significant 
increase of cholesterol (TC) and triacylglycerol levels (TAG). 
Two-way ANOVA was used to analyze the main and interaction effects of treatment and 
time on the phenotype. The 2 factors were treatment (Ad-PCSK9 or control virus Ad-Null) and time. 
Two-way ANOVA for significant differences was performed between the mean values of the 
phenotypes of Ad-PCSK9 and Ad-Null, and for the relationship between treatment and time. The 
results are shown in Table 3. The analyses demonstrated that overexpression of PCSK9 significantly 
increased cholesterol and TAG levels in all the mice studied. The interaction effects of treatment and 
time on the phenotype were significantly different.  
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Figure 6. The levels of plasma cholesterol and triacylglycerol in C57BL/6, Ldlr-/-, and 
LDb mice after transduction with Ad-PCSK9 or Ad-Null.  
C57BL/7, Ldlr-/-, and LDb mice were transduced with either 1010 viral particles (VP) Ad-Null 
or Ad-PCSK9. The open bars represent the value of plasma cholesterol and TAG, 
respectively, from Ad-Null treated mice. The closed bars represent the levels of plasma 
cholesterol and TAG, respectively, from the Ad-PCSK9 treated mice. * Statistical analysis 
was performed using 2-way ANOVA, and the difference between the Ad-PCSK9 and Ad-Null 
groups was highly significant.  
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Figure 7. The one-way ANOVA analysis of plasma cholesterol and TAG levels after 
Ad-PCSK9 transduction.  
The one-way ANOVA shows significant difference in the levels of plasma cholesterol (top 
panel) and triacylglycerol (bottom panel) between Ad-PCSK9 treated and Ad-Null treated 
C57BL/6, Ldlr-/-, and LDb mice. The one-way ANOVA was performed using STATASE 
software. 
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Table 2. One-way ANOVA (Treatment comparison of Ad-Null versus Ad-PCSK9) on plasma 
cholesterol and triacylglycerol levels in wild-type C57BL/6J, Ldlr-/-, and LDb mice. P values are 
shown. P < 0.05 is significant. 
 Treatment p Values (Ad-PCSK9 versus Ad-Null) 
 Day-0 Day-7 Day-14 Day-21 Day-30 
Cholesterol      
C57BL/6 0.6874 0.0000 0.0000 0.0000 0.0008 
Ldlr-/- 0.8958 0.0100 0.0002 0.0005 0.0017 
LDb 0.5244 0.0001 0.0066 0.0175 0.0021 
      
Triacylglycerol      
C57BL/6 0.1519 0.0000 0.0000 0.0000 0.0014 
Ldlr-/- 0.1668 0.0000 0.0001 0.0061 0.0000 
LDb 0.5582 0.0000 0.0000 0.0357 0.0098 
      
Cholesterol and triacylglycerol levels in wild-type C57BL/6J, Ldlr-/-, and LDb mice. P values are 
shown. P < 0.05 is significant. 
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Table 3. Two factors (Treatment and Time) ANOVA on plasma cholesterol and triacylglycerol 
levels in wild-type C57BL/6, Ldlr-/- and LDb mice treated with Ad-Null and Ad-PCSK9. P 
values are shown. 
 Main Factor   Interaction 
 Treatment Time  Treatment x Time 
Cholesterol     
C57BL/6 0.0000 0.0000  0.0000 
Ldlr-/- 0.0000 0.0081  0.0360 
LDb 0.0000 0.0000  0.0000 
     
Triacylglycerol     
C57BL/6 0.0000 0.0000  0.0000 
Ldlr-/- 0.0000 0.0000  0.0000 
LDb 0.0000 0.0000  0.0000 
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6. Overexpression of PCSK9 increases the levels of VLDL, LDL, but not HDL 
We used Fast Protein Liquid Chromatography (FPLC) technique to separate mouse plasma 
into VLDL, LDL, and HDL fractions. We measured the cholesterol and TAG levels of each fraction. 
In agreement with the total plasma lipid data on Figure 6, VLDL and LDL, but not HDL fractions 
had increased cholesterol and TAG levels in all the 3 mouse models that overexpressed PCSK9 
(Figures 8A and 8B, respectively). Overexpression of PCSK9 had the most significant effect on the 
levels of cholesterol and TAG in VLDL and LDL fractions of wild-type C57BL/6 mice. These may 
be the result of decreasing LDLR in C57BL/6 mice. The most interesting finding was that the 
increase of TAG levels in VLDL fractions in all 3 mouse models, suggesting that PCSK9 expression 
promoted VLDL production, irrespective of the LDLR. 
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Figure 8. The levels of cholesterol and TAG in VLDL and LDL in C57BL/6, Ldlr-/-, and 
LDb mice transduced with Ad-Null or Ad-PCSK9. (A) C57BL/6 (orange), Ldlr-/- (blue), 
and LDb (Pink) mice were transduced with either Ad-PCSK9 (closed circle) or Ad-Null (open 
circle). Pooled plasma samples from each group at indicated time were fractionated by FPLC. 
The fractionated plasma was subjected to cholesterol measurement using a commercial kit. 
Total cholesterol from each fraction was expressed as mg/dL. Positions of VLDL, LDL, and 
HDL are marked. (B) C57BL/6 (orange), Ldlr-/- (blue), and LDb (Pink) mice were transduced 
with either Ad-PCSK9 (closed circle) or Ad-Null (open circle). Pooled plasma samples from 
each group at indicated time were fractionated by FPLC. The fractionated plasma was 
subjected to TAG measurement using commercial kit. TAG from each fraction was expressed 
as mg/dL. Positions of VLDL, LDL, and HDL are marked. 
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7. Overexpression of PCSK9 increases plasma apoB levels in an LDLR-independent fashion. 
The increased VLDL and LDL levels in mice overexpression PCSK9 can be attributed to the 
elevated apoB production, which enhances the lipids export from the liver. Here we used Western 
blot analysis to determine the changes of apoB levels upon overexpression of PCSK9 in the 3 animal 
models. As shown in Figure 9, at day 7 after Ad-PCSK9 transduction, both plasma apoB-100 and 
apoB-48 levels rose markedly and remained elevated throughout the 30-day study. In C57BL/6 mice, 
upon overexpression of PCSK9 apoB-100 levels increased 1.93-, 3.79-, 2.22-, and 1.68-fold on days 
7, 14, 21, and 30, respectively, compared to day 0 before treatment. Likewise, apoB-48 levels were 
increased 3.53-, 4.73-, 4.34-, and 2.0-fold on days 7, 14, 21, and 30, respectively. Similar increases 
in apoB-100 levels were also observed in LDb mice from day 7 to day 30 upon PCSK9 expression. 
In Ldlr-/- mice, the increase in apoB-100 and apoB-48 levels only became prominent at day 14 and 
remained elevated to day 30.   
We measured the plasma apoAI and apoE levels in these 3 mouse models upon 
overexpression of PCSK9. As shown in Figure 10, there was no obvious difference in plasma apoAI 
and apoE levels upon overexpression of PCSK9 in Ldlr-/- and LDb mice. However, plasma apoE 
levels were increased in C57BL/6 mice after treatment. There was no difference in apoAI levels in 
C57BL/6 mice after treatment. 
  
C
A
d
N
ll
57BL/6 
Ldlr-/- 
LDb 
Figure 9. W
C57BL/6, L
microliter o
blotting wit
of plasma ap
 
A
d-
N
ul
l 
A
d-
Day-0 
estern blot 
dlr-/-, and L
f the plasma
h anti-mouse
oB are mark
A
d-
A
d-
N
ul
l 
Day-7 
analysis of p
Db mice w
 from each m
 apoB. The p
edly elevated
59 
A
d-
N
ul
l 
A
d-
PC
SK
9 
Day-14
lasma apolip
ere transduce
ouse was su
ositions of ap
 in mice tran
A
d-
N
ul
l 
A
d
PC
SK
9
 Day-2
oprotein B.
d with eithe
bjected to SD
oB-100 and 
sduced with 
A
d-A
d-
PC
SK
9 
1 Day
 
r Ad-PCSK
S-PAGE, fo
apoB-48 are
Ad-PCSK9. 
A
d-
PC
SK
9 
-30 
ApoB
ApoB
Apo
ApoB
ApoB
9 or Ad-Nul
llowed by W
 marked. The
-100 
-100 
B-100 
-48 
-48 
l. One 
estern 
 levels 
  
C
ApoA
Apo
ApoA
Apo
Ldlr-
ApoA
Apo
57BL/6 
LD
Figure 10
C57BL/6,
microliter
blotting w
was no o
Ldlr-/- an
treatment
 
-I 
A
d-
N
ul
l 
Da
E 
-I 
E 
-I 
E 
. Western b
 Ldlr-/-, and
 of the plasm
ith anti-mou
bvious differ
d LDb mice
. There was n
A
d-
PC
SK
9 
A
d-
N
ul
l 
y-0
lot analysis o
 LDb mice 
a from each
se apoA-I or
ence in plasm
. However, 
o difference 
60 
A
d-
PC
SK
9 
Day-7
f plasma ap
were transdu
 mouse was 
 apoE. The p
a apoAI and
plasma apoE
in apoAI lev
A
d-
N
ul
l 
A
d-
PC
SK
9 
Day-14
oA-1 and ap
ced with ei
subjected to 
ositions of a
 apoE levels
 levels were
els in C57BL
A
d-
N
ul
l 
A
d
PC
SK
9
Day-21
oE.  
ther Ad-PCS
SDS-PAGE,
poA-I and ap
 upon overex
 increased in
/6 mice after
A
d-
N
ul
l 
A
d-
PC
SK
9 
 Day
K9 or Ad-N
 followed by
oE are mark
pression of P
 C57BL/6 m
 treatment. 
A
d-
PC
SK
9 
-30
ull. One 
 Western 
ed. There 
CSK9 in 
ice after 
61 
 
8. Overexpression of PCSK9 increases apoB levels in VLDL and LDL 
We then investigated the apoB, apoE, and apoAI levels by Western blot analysis in VLDL, 
LDL, and HDL fractions. We analyzed samples from LDb mice only. Upon overexpression of 
PCSK9 in LDb mice, the apoB-100 levels were increased in VLDL and LDL fractions as shown in 
Figure 11A. Unlike plasma apoE levels, the apoE levels in VLDL and LDL fractions were elevated 
in LDb mice treated with Ad-PCSK9, whereas there were no obvious changes in ApoAI levels in 
HDL fractions (Figure 11B).   
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9. The influences of overexpression of PCSK9 on cholesterol and triacylglycerol synthesis 
pathway are not obvious 
To investigate whether overexpression of PCSK9 alters the cholesterol or lipid synthesis 
pathway, we measured the genes and proteins expression levels on the key enzymes and 
transcriptional factors that play regulatory roles. The sequences of primers and probes specific for 
each gene are listed in Table 1. We performed real-time quantitative PCR to measure the mRNA 
levels of each gene, and we did Western blot analysis to detect the protein levels. The results were 
analyzed by one-way and 2-way ANOVA.  
HMG-CoA synthetase and HMG-CoA reductase are the 2 key enzymes in cholesterol 
biosynthesis pathway. Acetyl-CoA carboxylase, fatty acid synthase, stearoyl-CoA desaturase-1, and 
glycerol-3-phosphate acyltransferase are the key enzymes in triacylglycerol biosynthesis pathway. 
SREBP1-a, and -1c are 2 very important transcriptional factors controlling fatty acid synthesis. 
SREBP-2 is the most important transcriptional factor that regulates intracellular cholesterol 
biosynthesis. Recent studies confirmed that it also regulates PCSK9 transcription. In this study, there 
were no obvious and consistent influences on gene expression levels by overexpression of PCSK9 
(Figures 12A, 12B, 12C, and Tables 4 and 5). Moreover, no significant differences were noted in the 
protein levels of these gene products, as determined by Western blot analysis (Figures 13A, 13B, and 
13C). Our results, in agreement with previous studies (16, 106), indicate that PCSK9 expression has 
no obvious effects on the genes governing cholesterol and TAG biosynthesis. 
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Table 4. One-way ANOVA (Treatment comparison of Ad-Null versus Ad-PCSK9) on 
gene expression levels of HMG-CoA Synthetase, HMG-CoA Reductase, Acetyl CoA 
Carboxylase, Fatty Acid Synthase, Stearoyl CoA Desaturase 1, Gpat, Srebp-1a, Srebp-1c, 
and Srebp-2 in wild-type C57BL/6J, Ldlr-/-, and LDb mice. P values are shown. P < 0.05 is 
significant, and it is highlighted in yellow. 
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  Treatment p Values (Ad-PCSK9 versus Ad-Null) 
 Day-0 Day-7 Day-14 Day-21 Day-30 
Cholesterol Biosynthesis 
Pathway 
     
HMG-CoA Synthetase      
C57BL/6 ND 0.4216 0.0835 0.1732 0.1432 
Ldlr-/- ND 0.0801 0.0212 0.0981 0.3680 
LDb ND 0.6386 0.3694 0.9376 0.9614 
      
HMG-CoA Reductase      
C57BL/6 ND 0.9586 0.5448 0.0715 0.0083 
Ldlr-/- ND 0.3779 0.4255 0.1378 0.0129 
LDb ND 0.0378 0.0002 0.2104 0.3894 
      
Triacyglycerol Biosynthesis 
Pathway 
     
Acetyl CoA Carboxylase      
C57BL/6 ND 0.1695 0.0290 0.0059 0.3819 
Ldlr-/- ND 0.1601 0.6349 0.1494 0.1316 
LDb ND 0.6952 0.4266 0.3352 0.0920 
      
Fatty Acid Synthase      
C57BL/6 ND 0.0161 0.2417 0.1472 0.2146 
Ldlr-/- ND 0.2185 0.0138 0.0367 0.0102 
LDb ND 0.1835 0.4190 0.0438 0.1348 
      
Stearoyl CoA Desaturase 1      
C57BL/6 ND 0.3099 0.4990 0.0770 0.2520 
Ldlr-/- ND 0.0113 0.7413 0.3064 0.2099 
LDb ND 0.6254 0.1146 0.0701 0.0692 
      
GPAT      
C57BL/6 ND 0.9806 0.3524 0.3543 0.1209 
Ldlr-/- ND 0.0853 0.4760 0.1848 0.0752 
LDb ND 0.3113 0.3922 0.2017 0.1738 
      
Transcription Factors      
Srebp-1a      
C57BL/6 ND 0.1242 0.6302 0.5772 0.9797 
Ldlr-/- ND 0.0538 0.1313 0.0356 0.0071 
LDb ND 0.0389 0.8713 0.3094 0.0967 
      
Srebp-1c      
C57BL/6 ND 0.4391 0.3391 0.1430 0.1980 
Ldlr-/- ND 0.0000 0.0000 0.0197 0.0492 
LDb ND 0.2306 0.0017 0.0133 0.0147 
      
Srebp-2      
C57BL/6 ND 0.8810 0.2403 0.0591 0.2943 
Ldlr-/- ND 0.0019 0.0230 0.4549 0.0236 
LDb ND 0.0498 0.3857 0.0831 0.0069 
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Table 5. Two factors ANOVA (Treatment and Time) on gene expression levels of HMG-
CoA Synthetase, HMG-CoA Reductase, Acetyl CoA Carboxylase, Fatty Acid Synthase, 
Stearoyl CoA Desaturase 1, Gpat, Srebp-1a, Srebp-1c, and Srebp-2 in wild-type C57BL/6, 
Ldlr-/- and LDb mice treated with Ad-Null and Ad-PCSK9. P values are shown. P < 0.05 is 
significant and highlighted in yellow. 
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 Main Factor   Interaction 
 Treatment Time  Treatment x Time 
Cholesterol Biosynthesis 
Pathway 
    
HMG-CoA Synthetase     
C57BL/6 0.0856 0.0000  0.0764 
Ldlr-/- 0.0044 0.4271  0.0882 
LDb 0.5509 0.0009  0.9090 
     
HMG-CoA Reductase     
C57BL/6 0.0074 0.1229  0.1426 
Ldlr-/- 0.0012 0.0961  0.1366 
LDb 0.1438 0.0367  0.0006 
     
Triacyglycerol 
Biosynthesis Pathway 
    
Acetyl CoA Carboxylase     
C57BL/6 0.8001 0.0130  0.0026 
Ldlr-/- 0.0079 0.9692  0.5416 
LDb 0.2554 0.2355  0.4541 
     
Fatty Acid Synthase     
C57BL/6 0.0261 0.0033  0.3490 
Ldlr-/- 0.0001 0.6776  0.6835 
LDb 0.0344 0.0333  0.0406 
     
Stearoyl CoA Desaturase 1     
C57BL/6 0.0819 0.0008  0.2912 
Ldlr-/- 0.0032 0.5816  0.1883 
LDb 0.0723 0.4741  0.0081 
     
GPAT     
C57BL/6 0.3159 0.2290  0.0372 
Ldlr-/- 0.0497 0.2812  0.0555 
LDb 0.0180 0.2013  0.5043 
     
Transcription Factors     
Srebp-1a     
C57BL/6 0.4698 0.0504  0.9677 
Ldlr-/- 0.0000 0.0956  0.2112 
LDb 0.3748 0.0068  0.0649 
     
     
Srebp-1c     
C57BL/6 0.0710 0.0003  0.1889 
Ldlr-/- 0.0000 0.2144  0.8080 
LDb 0.0019 0.0000  0.0000 
     
Srebp-2     
C57BL/6 0.0183 0.0598  0.4803 
Ldlr-/- 0.0000 0.2887  0.2896 
LDb 0.3211 0.5116  0.0796 
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10. Overexpression of PCSK9 has no effect on apoB mRNA levels in mice. 
To investigate the effect of PCSK9 on apoB mRNA levels, we used real-time quantitative 
PCR to determine the apoB mRNA levels. As shown in Figure 14, upon over-expression of PCSK9, 
there was no difference on apoB mRNA levels when comparing the Ad-PCSK9 group with Ad-Null 
group. These results suggested that the increased apoB levels upon overexpression of PCSK9 might 
be regulated posttranscriptionally.   
It is worth noting that the apoB mRNA levels in Ldlr-/- mice were 2-fold higher than that of 
C57BL/6 mice. The apoB mRNA levels in LDb mice were 4-fold higher than that of C57BL/6 mice. 
The reason that deficiency of LDLR resulted in increased apoB mRNA levels was not clear, but the 
increased apoB mRNA levels in Ldlr-/- and LDb mice are correlated with increased apoB production 
at baseline when compared with wild-type C57BL/6 mice (Figure 9). In Ldlr-/- mice, apoB-100 and 
apoB-48 levels were 1.98- and 2.69 fold higher than that of C57BL/6 mice, whereas LDb mice had 
1.28 fold higher apoB-100 levels than that of C57BL/6 mice.   
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Figure 14. Quantitative RT-PCR apoB gene expression analysis from C57BL/6, Ldlr-/-, and 
LDb mice after transduction with Ad-Null or Ad-PCSK9.  
Total RNAs were extracted from the livers of the mice transduced with Ad-Null or Ad-PCSK9. 
RNAs were subjected to reverse transcription into cDNA and the gene expression levels were 
detected by Taqman primers and probe real-time PCR. The results were normalized with 18S 
RNA and presented as mean ± SD. The black bars represent Ad-PCSK9 group and the open bars 
represent Ad-Null group. 
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11. PCSK9 is associated with VLDL and LDL, but mostly with LDL  
Next, we determined whether PCSK9 is associated with apoB-containing lipoprotein 
particles. We measured endogenous mouse plasma PCSK9 levels in non-treated C57BL/6, Ldlr-/-, 
and LDb mice by using ELISA (92 ± 7.8, 2015 ± 140, and 1646 ± 380 ng/mL, respectively); mice 
lacking LDLR had ~20-fold more PCSK9 than wild-type C57BL/6 mice. Interestingly, the apoB 
levels of Ldlr-/- and LDb mice were ~ 2- and 1.2-fold, respectively higher than that of wild-type 
C57BL/6 as determined by Western blot analysis. These results suggest that the regulation of PCSK9 
and apoB are probably tightly associated intracellularly. 
We also used ELISA to measure the endogenous mouse PCSK9 levels in the lipoprotein 
fractions. It shows that 30% and 41% of the plasma PCSK9 was associated with LDL in Ldlr-/- and 
LDb mice, respectively (Figure 15). The PCSK9 level in the fractions of C57BL/6 mice was too low 
to calculate the distribution percentage. Taken together, our results demonstrate that a substantial 
amount of endogenous PCSK9 is associated mostly with LDL in the circulation. 
Next, we used ELISA to determine the distribution of overexpressed human PCSK9 in 
plasma lipoproteins. Unlike endogenous mouse PCSK9 distribution, a small percentage of 
recombinant human PCSK9 was in LDL fractions of C57BL/6, Ldlr-/-, and LDb mice; 11%, 16%, 
and 17%, respectively. Western blot analysis shows that PCSK9 was predominantly present in the 
LDL fractions from day 7 to day 30 in LDb mice (Figure 16A). When we concentrated the plasma 
fractions of VLDL, LDL, and HDL of C57BL/6, LDb, and Ldlr-/- mice, PCSK9 was detected in both 
VLDL and LDL, but not in HDL fractions, as shown on day 7 after Ad-PCSK9 transduction (Figure 
16B). These results indicate that PCSK9 is associated with both VLDL and LDL, but mostly with 
LDL particles.  
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Figure 15. PCSK9 is associated with VLDL and LDL, but mostly with LDL.  
(A) Association of endogenous mouse PCSK9 with lipoproteins. Plasma samples of C57BL/6, 
Ldlr −/−, and LDb mice were fractionated by fast protein liquid chromatography (FPLC). The 
levels of total cholesterol (mg/dL) and mouse PCSK9 (ng/mL) were determined. The total 
cholesterol levels are shown as open squares, and the mouse PCSK9levels are shown as closed 
circles.  
(B) The proportions of PCSK9 levels associated with LDL fractions. PCSK9 levels in the 
fractionated mouse plasma were measured with standard ELISA procedure according to the 
company manual. The total amount of PCSK9 levels in the LDL fractions was calculated 
according to the volume of the plasma loaded into the FPLC system. The data were presented as 
percentages of LDL associated PCSK9 in total loaded plasma PCSK9. 
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12.   PCSK9 interacts with apoB intracellularly. 
Next, we asked the question whether PCSK9 interacts with apoB intracellularly. We used 3 
different approaches to investigate the interaction of PCSK9 with apoB.   
Co-immunoprecipitation of PCSK9 with apoB: We obtained 2 McA-RH7777 cell lines that stably 
expressed apoB-18 and apoB-48 from Dr. Zemin Yao at University of Ottawa, Canada. Human 
apoB-18 and apoB-48 cell lines express the N-terminal 18% and 48% of the full-length apoB-100, 
respectively. The cells were plated onto a 6-well plate, followed by infection with either Ad-PCSK9 
or Ad-Null overnight. On the next day, cell media and cell lysates were collected. We used either 
M2-anti-FLAG antibody or anti-apoB monoclonal 1D1 antibody to immunoprecipitate the 
PCSK9/apoB complex. As shown in Figure 17, apoB-18 and apoB-48 co-immunoprecipitated with 
PCSK9 in both cell lysates and cell media by using either anti-Flag antibody or anti-apoB-1D1 
antibody. ApoB was not detected in the precipitates from the control cells transduced with Ad-Null. 
These results suggested that PCSK9 could bind to amino acid sequences within the N-terminal 
region of apoB, namely, apoB-18. In addition, the association of PCSK9 with apoB occurred both 
intracellularly and in the media. We failed to co-immunoprecipitate apoB100 with PCSK9. The 
reason for the failure was unclear. 
Mammalian two-hybrid system: We used a mammalian two-hybrid system which expresses secreted 
alkaline phosphatase (SEAP) as the reporter (107) to determine the interaction of apoB and PCSK9 
proteins. We cloned apoB-18 to pM vector and PCSK9 to pVP-16 vector. We used pM vector 
containing Apobec1 as the negative control and pM vector containing LDL receptor as the positive 
control. We co-transfected 293 cells and COS-1 cells with the following combinations of plasmid 
vectors and the reporter vector pG5SEAP is present in all the experiments; pVP16-PCSK9/pM-
apoB18, pM-ApoB18/pVP16, pVP16-PCSK9/pM, pM-Apobec1/pVP16-PCSK9, and pM-
LDLR/pVP16-PCSK9, pM-LDLR/pVP16, pM/pVP16-PCSK9, and non-transfected. The cells 
expressed both ApoB-18 and PCSK9 resulted in >10-fold SEAP activity as measured by ELISA, 
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compared to the controls (i.e., transfected with pVP16-PCSK9/pM, pM-apoB18/pVP-16, pM-
Apobec1/pVP16-PCSK9, or pM/pVP16) (Figures 18A and 18B). The interaction of PCSK9/apoB-18 
in 293 cells was even stronger than that of PCSK9/LDLR (Figure 18C). These results suggest that 
PCSK9 binds to apoB intracellularly. 
In situ proximity ligation assay (PLA): The in situ proximity ligation assay, termed Duolink in situ 
PLA, detects endogenous protein–protein interaction (within 40 nm) at physiological concentrations 
with a very high specificity (108). To optimize the conditions of the assay, we first performed 
immunofluorescence assay to make sure the antibody can detect the intracellular proteins such as 
PCSK9, apoB, or LDLR in cells. In HepG2 cells, apoB and PCSK9 were detected in the cytoplasm, 
whereas the LDLR was localized on the cell membrane (Figure 19A). In HepG2 cells stably 
expressing Apobec1, Apobec1 and PCSK9 were also detected in the cytoplasm (Figure 19A).  
The endogenous apoB-100 interacts with PCSK9 in the cytoplasm of HepG2 cells 
(ApoB/PCSK9), as demonstrated by Duolink in situ PLA shown as red dot signals (Figure 19B). 
As expected, there was also a detectable interaction between PCSK9 and LDLR (LDLR/PCSK9). 
In HepG2 stably expressing Apobec1 cells, the Apobec1 did not interact with PCSK9 
(Apobec1/PCSK9), but there was a strong interaction between apoB and PCSK9 
(ApoB/PCSK9) again in the cytoplasm of these cells (Figure 19B). The following control 
experiments were performed, which are shown in Figure 19C. There was no interaction between 
PCSK9 and GAPDH, nor apoB and GAPDH. The experiments of anti-apoB only, or anti-PCSK9 
only, or no antibody control are also shown in Figure 19C. Collectively, these 3 different approaches 
confirmed a physical interaction between PCSK9 and apoB within the hepatocytes.  
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Figure 18. The protein–protein interaction between PCSK9 and apoB18 was observed 
with a mammalian matchmaker two-hybrid system.  
The 293 and COS-1 cells were transfected with the indicated plasmids. At 48 h after 
transfection, the secreted alkaline phosphatase (SEAP) activities in the cell media were 
assayed. The results are expressed as light unit (mean ± SD). Control assays included pM-
apoB18/pG5SEAP, pVP16-PCSK9/pG5SEAP, pM/pVP16/pG5SEAP, pM-Apobec1/pVP16-
PCSK9/pG5SEAP, and pG5SEAP. The pM-LDLR/pVP16-PCSK9 pair in 293 cells was used 
as a positive control. The assay was carried out 3 times with duplicate samples.  
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Figure 19. Immunostaining and Duolink in situ proximity ligation assay analysis of PCSK9 
and apoB.  
(A) Immunofluorescence staining of endogenous apoB, PCSK9, and LDLR in liver 
hepatocellular cells (HepG2 cells; top), and those plus Apobec1 in HepG2 stably expressing 
Apobec1 cells (bottom). The images were captured using a Leica DM 600B confocal microscope 
with 488 nm, 594 nm, and 633 nm filters. The experiments were performed in triplicate.  
(B) Protein–protein interaction of endogenous PCSK9 and apoB using Duolink in situ 
proximity ligation assay (PLA) in HepG2 cells (top) and HepG2 stably expressing Apobec1 
cells (bottom). The in situ PLA was performed using primary antibodies, including anti-apoB (α-
ApoB), anti-PCSK9 (α-PCSK9), anti-LDLR (α-LDLR), and anti-Apobec1 (α-Apobec1).  
(C) Controls for the PLA in HepG2 cells. The in situ PLA was performed using primary 
antibodies, including anti-apoB (α-ApoB), anti-PCSK9 (α-PCSK9), anti-GADPH.  
The images were captured using a Zeiss Axio Observer D1m fluorescence microscope with 4',6-
diamidino-2-phenylindole (DAPI), fluorescein isothiocyanate (FITC), and Texas Red filters. The 
red dots represent the positive protein–protein interaction of apoB with PCSK9 (α-ApoB/α-
PCSK9) and LDLR with PCSK9 (α-LDLR/α-PCSK9). The blue nuclear staining is DAPI. Each 
experiment was performed in triplicate. 
(C) 
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13. The interaction of PCSK9 with apoB increases apoB biosynthesis, irrespective of LDL 
receptor. 
We next performed pulse-chase experiments to determine the impact of the PCSK9/apoB 
interaction on apoB biosynthesis by using primary hepatocytes isolated from C57BL/6, Ldlr-/-, and 
LDb (Ldlr-/-Apobec1-/-) mice. The hepatocytes were transduced with either Ad-PCSK9 or Ad-Null 
vectors overnight. The hepatocytes were then pulsed with 35S-methionine/cysteine for 15 min, and 
chased for 30, 60, 120, 180, and 240 min. PCSK9 expression in the hepatocytes of C57BL/6 mice 
significantly increased the incorporation of 35S-methionine/cysteine into apoB-100 and apoB-48 in 
cell lysates, as compared to Ad-Null transduced cells (Figure 20A). Similarly, primary hepatocytes 
of Ldlr-/- mice expressing PCSK9 had significantly increased incorporation of 35S-
methionine/cysteine into apoB-100 and apoB48 in both cell lysates and media (Figure 20B), and the 
incorporation of methionine into apoB-100 in LDb mice was approximately 3-fold higher than that in 
either C57BL/6 or Ldlr-/- mice (Figure 20C). The effect of PCSK9 expression on apoB synthesis is 
specific, because no effect was observed for albumin synthesis (Figure 20D). Thus, our results 
demonstrated that PCSK9 increased apoB biosynthesis in C57BL/6 mice containing the LDL 
receptor and in Ldlr-/- and LDb mice deficient for the LDL receptor. The increased production of 
apoB in PCSK9-transduced hepatocytes could not be attributed to the increase of ApoB gene 
expression, because quantification of the apoB mRNA in the liver showed no difference between 
animals treated with Ad-PCSK9 and Ad-Null (Figure 14).  
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14.   The interaction of PCSK9 and apoB hindered apoB degradation pathway via 
autophagosome 
We next determined whether the interaction of PCSK9/apoB has any effect on intracellular 
degradation of apoB. The newly synthesized apoB can be degraded either through ubiquitin-
mediated proteasomal degradation (82) or by non-proteasomal degradation, the latter of which 
involves autophagosomes. (109) Autophagosomes are membrane structures that enclose intracellular 
substrates and deliver them to lysosomes for disposal, a process termed autophagy. (110) The apoB 
protein has been shown to accumulate in this structure, which is in close proximity to cytosolic lipid 
droplets. (109) It is suggested that autophagy may represent an alternative pathway for the disposal 
of apoB. (111) Here, we investigated whether PCSK9 regulates apoB levels via autophagy. 
Initially, we did the experiment of the autophagic apoB degradation in McA-RH7777 cell 
lysates. We transfected McA-RH7777 cells with pcDNA3-PCSK9 vector. At 48 h after transfection, 
we collected cell lysates and analyzed molecules involved in autophagy pathway including Beclin-1, 
Atg5, Atg7, LC3-I, and LC3-II by Western blot analysis. As shown in Figure 21A, there was no 
obvious difference between cells that overexpressed PCSK9 and the control cells. We thought the 
crude cell lysates might not be a good source for autophagy analysis. We then decided to purify 
autophagosomes from cells to analyze the effect of PCSK9 on apoB degradation. 
We transfected pcDNA-PCSK9 and pcDNA3 into McA-RH7777 cells and we then purified 
autophagosomes to determine the concentration of apoB and LC3-II in isolated autophagosomes. As 
shown in Figure 21B, the ratios of apoB-100:LC3-II and apoB-48:LC3-II were significantly lower in 
cells expressing PCSK9 than in the control cells transfected with pcDNA3 vector. Thus, expression 
of PCSK9 in McA-RH7777 cells resulted in decreased apoB (apoB-100 and apoB-48) levels in 
autophagosomes. 
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To investigate the effect of endogenous PCSK9 on apoB levels, we compared the apoB 
levels in hepatic autophagosomes isolated from C57BL/6 and Pcsk9-/- mice. As shown in Figure 
21C, mice lacking Pcsk9 (Pcsk9-/-) had significantly increased ratio of apoB-100:LC3-II and apoB-
48:LC3-II in autophagosomes, compared to C57BL/6 mice. 
Finally, we determined whether the effect of PCSK9 on apoB degradation was dependent 
upon the LDLR. We compared the effect on autophagosomes from LDb mice and triple knockout 
mice LDbPcsk9-/- (LDb = Ldlr-/-Apobec1-/-Pcsk9+/+ mice and LDbPcsk9-/- = Ldlr-/-Apobec1-/-
Pcsk9-/- mice). Similar to what was observed in McA-RH7777 cells and C57BL/6 versus Pcsk9-/- 
mice, the ratio of apoB-100:LC3-II was significantly lower in LDb mice (Ldlr-/-Apobec1-/-
Pcsk9+/+), compared to that in LDbPcsk9-/- triple knockout mice (Ldlr-/-Apobec1-/-Pcsk9-/-) 
(Figure 21D). Thus, there was less apoB in the autophagosomes in Pcsk9-positive mice (LDb), which 
suggested that decreased amount of apoB was shunted to autophagosomes for degradation. These 
results together suggest that PCSK9 expression in the mouse liver protects/inhibits apoB from 
autophagic degradation, and the protection of apoB by PCSK9 is independent of the LDLR.  
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15. LDbPCSK9-/- mice have decreased cholesterol, TAG, and apoB levels, compare to LDb 
mice. 
Our study has demonstrated an important new role of PCSK9 that interacts with apoB, which 
inhibits intracellular degradation of apoB via the autophagosome/lysosome pathway, and this, in 
turn, results in increased secretion of apoB-containing lipoproteins, leading to increased cholesterol 
and triglyceride levels. This process is irrespective of the presence of LDLR. To confirm the role of 
PCSK9 in regulating apoB production, we crossbred LDb mice with Pcsk9-/- mice to generate a 
triple knockout mouse model (Ldlr-/-Apobec1-/-Pcsk9-/-). 
As shown in Figure 22, in comparison of LDbPcsk9-/- triple knockout mice with LDb mice 
there was no significance difference in body weight or the lean and fat ratio of these 2 group mice at 
4 months of age. Importantly, deleting of the Pcsk9 from LDb mice (LDbPcsk9-/-) resulted in 
significant decrease of plasma cholesterol (decreased 25%), TAG (decreased 33%), and apoB 
(decreased 38%) levels (Figure 23), when compared to LDb mice. FPLC analysis showed that the 
levels of cholesterol and triglyceride in VLDL and LDL were markedly decreased (Figure 23). Thus, 
our results corroborated that PCSK9 is an important molecule that regulates apoB production in the 
absence of LDL receptor. 
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Figure 22. The comparisons of body weight of LDbPcsk9-/- triple knockout mice and 
LDb mice.  
LDbPcsk9-/- triple knockout mice and LDb mice have similar body weight or the lean and 
fat ratio at 4 months of age. The LDbPcsk9-/- and LDb were measured for total, fat, and 
lean body weights by Eco-MIR. The data are presented as mean ± SD.  p value of <0.05 is 
considered significant difference. 
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DISCUSSION 
The current study demonstrates that long-term overexpression of PCSK9 in mice increases 
plasma cholesterol, TAG, and apoB levels, irrespective of the presence of the LDLR. PCSK9 
interacts with apoB to prevent/inhibit/decrease the mobilization of apoB towards autophagosomes 
for degradation via autophagosome/lysosome pathway. This, in turn, results in increased production 
and secretion of apoB and apoB-containing lipoprotein. Significantly, mice deficient of Pcsk9 in the 
background without the LDLR had lower levels of plasma cholesterol, TAG, and apoB, which 
indicate PCSK9 regulates apoB production independent of LDLR. Most importantly, our study 
demonstrates a direct protein–protein interaction of PCSK9 and apoB in cells under physiological 
conditions. This interaction also exists in the circulation. Taken together, these data established that 
PCSK9 regulates lipoprotein and apoB metabolism independent of the LDLR. This study provides a 
new concept that PCSK9 interacts with apoB and regulates apoB degradation, which implicates the 
therapeutic importance of lower PCSK9 levels to reduce the production/secretion of apoB-containing 
lipoproteins.  
The new role of PCSK9 regulates apoB production, irrespective of LDL receptor              
Early investigations in cells (27), mice, (103) and humans (97) have suggested that PCSK9 
might play a role in regulating apoB production, but some other studies failed to observe the effects 
of PCSK9 on apoB production (98, 99). Studies in mice using first-generation adenoviral vector 
expressing PCSK9 for 3–6 days did not see any significant change in apoB- containing lipoprotein 
levels, whereas one study extended to 7 days observed the increase of apoB levels in Ldlr-/- mice. To 
circumvent this problem, we used a 2nd generation adenoviral vector system to express PCSK9 in a 
longer term. This vector can express transgene for more than one month with a very low toxicity (94). 
Our study demonstrated the long-term gene expression ability of this 2nd generation vector system.  
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By doing so, we observed a consistent increase of the VLDL and LDL cholesterol levels in wild-
type C57BL/6 mice and LDLR deficient mouse models of Ldlr-/- and LDb mice. Our result 
demonstrated that PCSK9 increases the VLDL and LDL levels, independent of LDLR. The most 
interesting finding is that the TAG and cholesterol levels in VLDL increased more dramatically than 
those of LDL, which indicated an enhanced VLDL production. So far, enhanced apoB and VLDL 
productions were only reported in 2 gain-of-function mutations: D374Y and S127R (27, 97). Our 
results, for the first time, showed that wild-type PCSK9 increases VLDL production, irrespective of 
LDLR. This finding is further supported by our work that deletion of PCSK9 from LDb mice 
(LDb/PCSK9-/- mice), resulting in decreased plasma levels of apoB, TAG, and cholesterol as well as 
the decreased levels of VLDL and LDL particles. Thus, our study demonstrated the role of PCSK9 
on apoB production is independent of LDLR. Pcsk-/- mice have been shown to have a reduction in 
lymphatic apoB secretion, compared with Pcsk+/+ mice (93), which suggested PCSK9 affected 
apoB production in small intestine. Taken together, a new role of PCSK9 in apoB production is 
defined. 
The potential impact of this study   
The PCSK9/LDLR interaction is a well-established mechanism, which elucidates how 
PCSK9 regulates LDL cholesterol levels. Based on this concept, different therapeutics was 
developed to block the PCSK/LDLR interaction, mainly, in the circulation or on the cell surface of 
hepatocytes. Recently REGN727, a PCSK9-specific monoclonal antibody product (Regeneron and 
Sanofi) has been shown to reduce LDL cholesterol ranging from 30% to more than 65% in a 12-
week Phase II trial involving 75 patients with heterozygous familial hypercholesterolemia exhibiting 
elevated LDL-C levels despite of statin therapy (112). Amegen also announced their Phase I clinical 
study of AMG 145, another PCSK9 monoclonal antibody, in patients with hypercholesterolemia 
(American College of Cardiology Scientific Session in Chicago; Abstract # 923-4). The study shows 
101 
 
that multiple doses of AMG 145 significantly reduced LDL-C by up to 81% in patients treated with 
statins versus placebo controls.  
With the emerging results of monoclonal antibody clinical trials, the ability of PCSK9 to 
lower LDL cholesterol in patients not compatible with statin treatment appears very hopeful. 
However, although monoclonal antibody is shown to be an effective way to blocking the 
PCSK9/LDLR interaction to lower LDL cholesterol, antibody regiment is very costly for a long-term 
usage. In our study, we demonstrated a new role of how PCSK9 regulates apoB production, thus, 
new therapeutic strategies targeting at both intra- and extracellular PCSK9 levels are warranted.  
The proposed mechanism of PCSK9/apoB interaction 
Zhang et al. (23) have demonstrated that PCSK9 selectively interacts with the EGF-A repeat 
of the LDLR (and not with other members of the LDLR family) in a calcium-dependent manner. 
Moreover, they have shown that the PCSK9-mediated degradation of the LDLR requires the ligand-
binding domain and the β-propeller domain of LDLR and the prodomain, the catalytic domain, and 
the C-terminal domain of PCSK9 for PCSK9-mediated degradation of the LDLR.  
In our study, we showed that there is a direct protein–protein interaction between PCSK9 
and apoB. We have shown that PCSK9 interacts with apoB-18 (18% of N-terminal of apoB), but we 
did not know the minimal sequences requirement of apoB that is needed to interact with PCSK9. 
Moreover, apoB is a 550,000 Da protein, it contains a lipid-binding domain, a RNA editing region, 
and a LDL receptor binding domain; we wondered whether any of these regions was required for the 
interaction of apoB with PCSK9. We are setting up experiments to delineate these questions. 
It was reported that the half-life of recombinant human PCSK9 in the circulation was 5 min 
(17). This raises the question whether the PCSK9 that was associated with LDL might have a longer 
half-life; or the PCSK9/LDL complex would have the same half-life as LDL, which is 3 days under 
normal physiological conditions, or, whether the PCSK9/LDL complex might bind to LDLR more 
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efficiently than free PCSK9. These are important questions to elucidate the function of PCSK9. We 
have shown that a substantial amount of PCSK9 (30–40%) was associated with LDL, and this 
PCSK9 could interact with apoB. Thus, PCSK9 could block the apoB-binding domain for LDLR, 
which leads to a consequence that PCSK9/LDL complex would not be able to bind to LDLR via 
apoB binding sites. All these questions will be our future study to delineate the structure/function 
relationship of PCSK9 and apoB.  
   In our study, we proposed that the impact of the interaction of PCSK9 with apoB was to 
inhibit the degradation of apoB via autophagosome/lysosome pathway, and this, in turn, results in 
increased secretion of apoB-containing lipoproteins to the circulation. We provided the evidence that 
animals or cells containing PCSK9 have less apoB in the autophagosomes, compared with those 
deficient of PCSK9. However, we did not propose a detailed mechanism on how the interaction of 
these 2 proteins might regulate autophagy, or whether this interaction would regulate autophagy 
process at all in the hepatocytes.  
It is known that PI3 kinase type I and III, which help recruit autophagic proteins, initiates the 
autophagy process (113). Several autophagy-related genes (Atg) that are evolutionarily conserved 
mediate the elongation process to start the autophagosomes process. The Atg genes recruit 
microtubule light chain-3 (LC3) to form the mature autophagosome. LC3 undergoes proteolytic 
cleavage and lipidation to yield LC3-II, this is the protein that associates with autophagic membrane 
and represents the mature autophagosomes. At this stage, the outer membrane of the 
autophagosomes fuses with a lysosome to form autophagolysosome. Lysosomal contents 
subsequently degrade the cytosolic components inside the autophagosomes (114).  
PI3 kinase type I is activated by growth factors such as insulin and inhibits autophagy 
through PDK1 and AKT, which regulates mammalian target of rapamycin (mTOR) (115). It is 
suggested that active PI3K/mTOR maintains autophagy at basal lower levels. It is still unclear how 
activation of mTOR inhibits autophagy, but the mechanism may involve phosphorylation of Atg13, 
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which is part of a protein complex with Atg1, a serine/threonine kinase (116). mTOR governs many 
downstream signaling pathways. Here, we propose that when mTOR was activated, it activated PKC 
δ, which activated HNF1alpha, SREBP2, and the production of PCSK9. The increased production of 
PCSK9 interacts with apoB to inhibit the degradation of apoB via autophagosome. At the same time, 
the activation of mTOR suppresses the autophagy. Thus, the activation of mTOR results in increased 
production of PCSK9 and decreased autophagy activity. This signaling pathway is a potential 
mechanism involving PCSK9, apoB, and autophagy (Figure D-1) in the hepatocytes. 
PI3 kinase type III, which includes Atg6 in its complex, promotes the nucleation of 
autophagic vesicles (117). Expansion of autophagic vesicles or the elongation of autophagosome is 
mediated by 2 ubiquitin-like conjugation systems: (1) the Atg12 pathway involves Atg12 (ubiquitin-
like), Atg7 (E1-like), Atg10 (E2-like), and Atg5. (2) The Atg8 pathway involves Atg8 (ubiquitin-
like), Atg7 (E1-like), Atg3 (E2-like), and Atg5. In the Atg12 pathway, Atg12 is conjugated to Atg5, 
while in the Atg8 pathway, Atg8 is conjugated to phosphatidylethanolamine (118).   
Autophagy is a dynamic process in biological and pathological process. Recent work by 
Razani et al. (119) demonstrated increased levels of p62 in atherosclerotic lesions, which suggested a 
dysfunctional autophagy process is associated with atherosclerosis development. Oxidized-LDL has 
been shown to be removed through autophagosome/lysosome pathway in human vascular endothelial 
cells (119). Also, engulfed LDL may be broken down in activated macrophages via the autophagy 
process (120). Thus, there are a lot of examples implicating autophagy with the atherosclerosis 
process. In our preliminary results, we detected PCSK9 in the atherosclerotic plaque in LDb mice. It 
would be interesting to determine whether the association of PCSK9 with LDL via apoB would 
inhibit the uptake of LDL via macrophages and in turn, hinder the removal of lipids via autophagy-
mediated efflux process. Our study, thus, has raised many unexpected questions related to 
PCSK9/apoB/LDL, which remain to be answered. 
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The ubiquitin proteasome pathway also plays a role in the quality control of apoB production. 
(121) The translated apoB is accompanied by the process of lipidation. If the lipidation does not 
perform well, nascent apoB cannot fold properly. Therefore, poorly lipidated and misfolded apoB 
will be detected by specialized factors within the ER and delivered to a ubiquitination machinery for 
degradation. This process is proteasomal apoB degradation pathway (121). Although the detailed 
mechanism remains to be defined, it is suggested that many chaperon molecules such as HSP70, 90, 
BiP/GRP78, GRP94, and ERp57 participate in this process (87, 88). In our study, we could not 
exclude the possibility that the interaction between PCSK9 and apoB might inhibit the ubiquitin-
proteasome degradation system. Further study will be needed to distinguish the influence of the 
interaction of PCSK9 with apoB on both of the apoB degradation pathways. 
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Figure D-1. The proposed signaling pathway involving PCSK9 and apoB interaction.  
After being activated by growth factor such as VEGF or insulin, PI3 kinase activates PDK-1, 
which then activates its downstream signaling molecule AKT-1. AKT-1 activates mTOR, the 
key molecule that inhibits autophagy. mTOR activates two important transcriptional factors, 
HNF-1 and SREBP2. Both of these two transcriptional factors can up-regulate PCSK9 
transcription. Increased PCSK9 interacts with apoB and inhibits its degradation through 
autophagy, which has been inhibited by activated mTOR. The overall outcome of this 
pathway is increased hepatic apoB production. 
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The role of PCSK9/apoB/LDLR: a proposed model. 
The mechanism that PCSK9 binds to LDLR and leads it to degradation has been well 
established. Here, we have demonstrated an important mechanism that PCSK9 interacts with apoB, 
and the consequence of this interaction leads to decreased degradation of apoB via the 
autophagosome/lysosome pathway. Thus, PCSK9 is a molecule that shuttles between apoB and 
LDLR. PCSK9 is the main regulator of apoB and LDLR production. 
In summary, the study provides evidence on how overexpressing PCSK9 increased 
cholesterol, TAG, and apoB levels independent of LDLR. Our study also opens up a proposed 
mechanism of how PCSK9 might regulate the autophagy process in lipid metabolism. Taken 
together, our results suggest that decreasing intracellular PCSK9 levels may be a promising 
therapeutic approach to regulate the production of atherogenic apoB-containing lipoproteins and thus 
prevent the development of atherosclerosis.  
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5. The future study. 
Based on our findings, many questions have been proposed. 
5.1. The structure/functional relationship of PCSK9 and apoB. 
ApoB: To determine the minimal length of apoB that is required to interact with PCSK9. We will 
use the mammalian two-hybrid system to investigate this minimal apoB length requirement for the 
interaction of PCSK9 with apoB. We will also construct clones deficient of apoB lipid binding 
domain, editing region, or LDL receptor binding domain to study if any of this domain is required 
for the interaction. 
PCSK9: We will make gain-of-function mutations such as D374Y and S127R and loss-of-function 
mutations such as Y142L to investigate whether these mutations have influence on the interaction of 
PCSK9 with apoB. 
 
5.2. To investigate the effect of PCSK9 on atherogenesis. 
As described before, we have generated a triple knockout mouse model (Ldlr-/-Apobec1-/-Pcsk9-/-). 
Based on this mouse model, we will delineate the influence of PCSK9 on atherogenesis. The 
mechanism in atherogenesis may be different from that in the hepatocytes. 
 
5.3. To delineate the molecular mechanism of the regulation of PCSK9 on apoB production 
in the liver. 
As discussed above, we proposed a signaling pathway indicating mTOR inhibits autophagy process 
and activates PCSK9 transcription. We will proceed step by step to approve or disapprove of the 
pathway to understand the interrelationship of PCSK9, apoB, and autophagy. We will investigate 
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whether hyperlipidemia regulates the upstream signaling of mTOR. Moreover, we will delineate 
whether ubiquitin-proteasome pathway play a role in the regulation of PCSK9 on apoB production.  
 
5.4. To define the miRNAs that regulate PCSK9. 
PCSK9 plays an important function in lipoprotein metabolism. It also plays a role in atherogenesis, 
since I have detected PCSK9 in atherosclerotic plaques. I have identified hsa-miR-601 and hsa-miR-
632 miRNAs that targeted PCSK9 to elucidate the mechanism of how miRNAs regulate PCSK9.    
 
5.5. To develop therapeutics to decrease PCSK9 levels. 
5.5.1 To block the interaction between PCSK9 and LDLR:  
Our laboratory is using a novel disulfide scrambling technique to generate vaccine to block the 
interaction between PCSK9 and LDLR. 
5.5.2 To design siRNA to inhibit the production of PCSK9:  
We have designed a couple of siRNAs targeted at human and mouse PCSK9 mRNA. PCSK9-
specific siRNA would decrease the production of PCSK9 intracellularly. 
5.5.3. To design RNA or DNA specific aptamer to target at PCSK9 to block the interaction of 
PCSK9 and apoB: T 
This strategy would be a better approach than using small molecules to block the protein–protein 
interaction.    
Finally, with the understanding of how PCSK9 regulates apoB, new PCSK9 intracellular inhibitory 
strategies appear more promising. Intracellular inhibition of PCSK9 by siRNA, anti-sense RNA, 
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intracellular antibodies, and kinase inhibitors can achieve this goal more efficiently than by only 
inhibiting free PCSK9 in the circulation. With the rapid development in the cancer therapy area, 
more and more safe and effective kinase inhibitors have entered the clinical trials. It is possible one 
of the current kinase inhibitors will have a very bright and promising future in lower PCSK9 levels. 
 
  
110 
 
REFERENCES 
1. Davignon, J., Dubuc, G., and Seidah, N.G. 2010. The influence of PCSK9 polymorphisms 
on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler 
Rep 12:308-315. 
2. Seidah, N.G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S.B., Stifani, S., 
Basak, A., Prat, A., and Chretien, M. 2003. The secretory proprotein convertase neural 
apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. 
Proc Natl Acad Sci U S A 100:928-933. 
3. Varret, M., Rabes, J.P., Saint-Jore, B., Cenarro, A., Marinoni, J.C., Civeira, F., Devillers, M., 
Krempf, M., Coulon, M., Thiart, R., et al. 1999. A third major locus for autosomal dominant 
hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet 64:1378-1387. 
4. Abifadel, M., Varret, M., Rabes, J.P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., 
Benjannet, S., Wickham, L., Erlich, D., et al. 2003. Mutations in PCSK9 cause autosomal 
dominant hypercholesterolemia. Nat Genet 34:154-156. 
5. Timms, K.M., Wagner, S., Samuels, M.E., Forbey, K., Goldfine, H., Jammulapati, S., 
Skolnick, M.H., Hopkins, P.N., Hunt, S.C., and Shattuck, D.M. 2004. A mutation in PCSK9 
causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 114:349-
353. 
6. Abifadel, M., Rabes, J.P., Devillers, M., Munnich, A., Erlich, D., Junien, C., Varret, M., and 
Boileau, C. 2009. Mutations and polymorphisms in the proprotein convertase subtilisin 
kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 30:520-529. 
7. Leren, T.P. 2004. Mutations in the PCSK9 gene in Norwegian subjects with autosomal 
dominant hypercholesterolemia. Clin Genet 65:419-422. 
8. Pisciotta, L., Priore Oliva, C., Cefalu, A.B., Noto, D., Bellocchio, A., Fresa, R., Cantafora, 
A., Patel, D., Averna, M., Tarugi, P., et al. 2006. Additive effect of mutations in LDLR and 
111 
 
PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis 186:433-
440. 
9. Bottomley, M.J., Cirillo, A., Orsatti, L., Ruggeri, L., Fisher, T.S., Santoro, J.C., Cummings, 
R.T., Cubbon, R.M., Lo Surdo, P., Calzetta, A., et al. 2009. Structural and biochemical 
characterization of the wild type PCSK9-EGF(AB) complex and natural familial 
hypercholesterolemia mutants. J Biol Chem 284:1313-1323. 
10. Cohen, J.C., Boerwinkle, E., Mosley, T.H., Jr., and Hobbs, H.H. 2006. Sequence variations 
in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264-
1272. 
11. Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K., and Hobbs, H.H. 2005. 
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense 
mutations in PCSK9. Nat Genet 37:161-165. 
12. Hooper, A.J., Marais, A.D., Tanyanyiwa, D.M., and Burnett, J.R. 2007. The C679X 
mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. 
Atherosclerosis 193:445-448. 
13. Kotowski, I.K., Pertsemlidis, A., Luke, A., Cooper, R.S., Vega, G.L., Cohen, J.C., and 
Hobbs, H.H. 2006. A spectrum of PCSK9 alleles contributes to plasma levels of low-density 
lipoprotein cholesterol. Am J Hum Genet 78:410-422. 
14. Tibolla, G., Norata, G.D., Artali, R., Meneghetti, F., and Catapano, A.L. 2011. Proprotein 
convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic 
inhibition. Nutr Metab Cardiovasc Dis 21:835-843. 
15. Maxwell, K.N., and Breslow, J.L. 2004. Adenoviral-mediated expression of Pcsk9 in mice 
results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 
101:7100-7105. 
16. Lagace, T.A., Curtis, D.E., Garuti, R., McNutt, M.C., Park, S.W., Prather, H.B., Anderson, 
N.N., Ho, Y.K., Hammer, R.E., and Horton, J.D. 2006. Secreted PCSK9 decreases the 
112 
 
number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 
116:2995-3005. 
17. Grefhorst, A., McNutt, M.C., Lagace, T.A., and Horton, J.D. 2008. Plasma PCSK9 
preferentially reduces liver LDL receptors in mice. J Lipid Res 49:1303-1311. 
18. Schmidt, R.J., Beyer, T.P., Bensch, W.R., Qian, Y.W., Lin, A., Kowala, M., Alborn, W.E., 
Konrad, R.J., and Cao, G. 2008. Secreted proprotein convertase subtilisin/kexin type 9 
reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem 
Biophys Res Commun 370:634-640. 
19. Rashid, S., Curtis, D.E., Garuti, R., Anderson, N.N., Bashmakov, Y., Ho, Y.K., Hammer, 
R.E., Moon, Y.A., and Horton, J.D. 2005. Decreased plasma cholesterol and hypersensitivity 
to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 102:5374-5379. 
20. Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M.C., 
Hamelin, J., Varret, M., Allard, D., et al. 2004. NARC-1/PCSK9 and its natural mutants: 
zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL 
cholesterol. J Biol Chem 279:48865-48875. 
21. Cunningham, D., Danley, D.E., Geoghegan, K.F., Griffor, M.C., Hawkins, J.L., Subashi, 
T.A., Varghese, A.H., Ammirati, M.J., Culp, J.S., Hoth, L.R., et al. 2007. Structural and 
biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat 
Struct Mol Biol 14:413-419. 
22. Zhang, D.W., Lagace, T.A., Garuti, R., Zhao, Z., McDonald, M., Horton, J.D., Cohen, J.C., 
and Hobbs, H.H. 2007. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal 
growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling 
and increases degradation. J Biol Chem 282:18602-18612. 
23. Zhang, D.W., Garuti, R., Tang, W.J., Cohen, J.C., and Hobbs, H.H. 2008. Structural 
requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc 
Natl Acad Sci U S A 105:13045-13050. 
113 
 
24. Piper, D.E., Jackson, S., Liu, Q., Romanow, W.G., Shetterly, S., Thibault, S.T., Shan, B., 
and Walker, N.P. 2007. The crystal structure of PCSK9: a regulator of plasma LDL-
cholesterol. Structure 15:545-552. 
25. Horton, J.D., Cohen, J.C., and Hobbs, H.H. 2007. Molecular biology of PCSK9: its role in 
LDL metabolism. Trends Biochem Sci 32:71-77. 
26. McNutt, M.C., Lagace, T.A., and Horton, J.D. 2007. Catalytic activity is not required for 
secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 
282:20799-20803. 
27. Sun, X.M., Eden, E.R., Tosi, I., Neuwirth, C.K., Wile, D., Naoumova, R.P., and Soutar, A.K. 
2005. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of 
unusually severe dominant hypercholesterolaemia. Hum Mol Genet 14:1161-1169. 
28. Nassoury, N., Blasiole, D.A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., 
McPherson, P.S., Attie, A.D., Prat, A., and Seidah, N.G. 2007. The cellular trafficking of the 
secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8:718-732. 
29. Kwon, H.J., Lagace, T.A., McNutt, M.C., Horton, J.D., and Deisenhofer, J. 2008. Molecular 
basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A 105:1820-1825. 
30. Surdo, P.L., Bottomley, M.J., Calzetta, A., Settembre, E.C., Cirillo, A., Pandit, S., Ni, Y.G., 
Hubbard, B., Sitlani, A., and Carfi, A. 2011. Mechanistic implications for LDL receptor 
degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep 12:1300-1305. 
31. Dong, B., Wu, M., Li, H., Kraemer, F.B., Adeli, K., Seidah, N.G., Park, S.W., and Liu, J. 
2010. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: 
mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic 
hamsters. J Lipid Res 51:1486-1495. 
32. Horton, J.D., Shah, N.A., Warrington, J.A., Anderson, N.N., Park, S.W., Brown, M.S., and 
Goldstein, J.L. 2003. Combined analysis of oligonucleotide microarray data from transgenic 
114 
 
and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 
100:12027-12032. 
33. Maxwell, K.N., Soccio, R.E., Duncan, E.M., Sehayek, E., and Breslow, J.L. 2003. Novel 
putative SREBP and LXR target genes identified by microarray analysis in liver of 
cholesterol-fed mice. J Lipid Res 44:2109-2119. 
34. Jeong, H.J., Lee, H.S., Kim, K.S., Kim, Y.K., Yoon, D., and Park, S.W. 2008. Sterol-
dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-
regulatory element binding protein-2. J Lipid Res 49:399-409. 
35. Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N.G., Bernier, L., and Prat, 
A. 2004. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural 
apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler 
Thromb Vasc Biol 24:1454-1459. 
36. Persson, L., Galman, C., Angelin, B., and Rudling, M. 2009. Importance of proprotein 
convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-
density lipoprotein receptors. Endocrinology 150:1140-1146. 
37. Cameron, J., Ranheim, T., Kulseth, M.A., Leren, T.P., and Berge, K.E. 2008. Berberine 
decreases PCSK9 expression in HepG2 cells. Atherosclerosis 201:266-273. 
38. Naoumova, R.P., Tosi, I., Patel, D., Neuwirth, C., Horswell, S.D., Marais, A.D., van 
Heyningen, C., and Soutar, A.K. 2005. Severe hypercholesterolemia in four British families 
with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. 
Arterioscler Thromb Vasc Biol 25:2654-2660. 
39. Berge, K.E., Ose, L., and Leren, T.P. 2006. Missense mutations in the PCSK9 gene are 
associated with hypocholesterolemia and possibly increased response to statin therapy. 
Arterioscler Thromb Vasc Biol 26:1094-1100. 
115 
 
40. Zhao, Z., Tuakli-Wosornu, Y., Lagace, T.A., Kinch, L., Grishin, N.V., Horton, J.D., Cohen, 
J.C., and Hobbs, H.H. 2006. Molecular characterization of loss-of-function mutations in 
PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79:514-523. 
41. Stein, E.A., Mellis, S., Yancopoulos, G.D., Stahl, N., Logan, D., Smith, W.B., Lisbon, E., 
Gutierrez, M., Webb, C., Wu, R., et al. 2012. Effect of a monoclonal antibody to PCSK9 on 
LDL cholesterol. N Engl J Med 366:1108-1118. 
42. Chan, J.C., Piper, D.E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., 
Xia, Z., et al. 2009. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody 
reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 
106:9820-9825. 
43. Graham, M.J., Lemonidis, K.M., Whipple, C.P., Subramaniam, A., Monia, B.P., Crooke, 
S.T., and Crooke, R.M. 2007. Antisense inhibition of proprotein convertase subtilisin/kexin 
type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 48:763-767. 
44. Lindholm, M.W., Elmen, J., Fisker, N., Hansen, H.F., Persson, R., Moller, M.R., 
Rosenbohm, C., Orum, H., Straarup, E.M., and Koch, T. 2012. PCSK9 LNA Antisense 
Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates. 
Mol Ther 20:376-381. 
45. Frank-Kamenetsky, M., Grefhorst, A., Anderson, N.N., Racie, T.S., Bramlage, B., Akinc, A., 
Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. 2008. Therapeutic RNAi targeting PCSK9 
acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. 
Proc Natl Acad Sci U S A 105:11915-11920. 
46. Goldstein, J.L., and Brown, M.S. 2001. Molecular medicine. The cholesterol quartet. Science 
292:1310-1312. 
47. Yokoyama, S. 2006. ABCA1 and biogenesis of HDL. J Atheroscler Thromb 13:1-15. 
48. Schmitz, G., Langmann, T., and Heimerl, S. 2001. Role of ABCG1 and other ABCG family 
members in lipid metabolism. J Lipid Res 42:1513-1520. 
116 
 
49. Jiang, X.C. 2002. The effect of phospholipid transfer protein on lipoprotein metabolism and 
atherosclerosis. Front Biosci 7:d1634-1641. 
50. Dobiasova, M., and Frohlich, J.J. 1999. Advances in understanding of the role of lecithin 
cholesterol acyltransferase (LCAT) in cholesterol transport. Clin Chim Acta 286:257-271. 
51. Barter, P.J., Brewer, H.B., Jr., Chapman, M.J., Hennekens, C.H., Rader, D.J., and Tall, A.R. 
2003. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting 
atherosclerosis. Arterioscler Thromb Vasc Biol 23:160-167. 
52. Kastelein, J.J., van Leuven, S.I., Burgess, L., Evans, G.W., Kuivenhoven, J.A., Barter, P.J., 
Revkin, J.H., Grobbee, D.E., Riley, W.A., Shear, C.L., et al. 2007. Effect of torcetrapib on 
carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356:1620-1630. 
53. de Grooth, G.J., Kuivenhoven, J.A., Stalenhoef, A.F., de Graaf, J., Zwinderman, A.H., 
Posma, J.L., van Tol, A., and Kastelein, J.J. 2002. Efficacy and safety of a novel cholesteryl 
ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response 
study. Circulation 105:2159-2165. 
54. Ma, P.T., Gil, G., Sudhof, T.C., Bilheimer, D.W., Goldstein, J.L., and Brown, M.S. 1986. 
Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein 
receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A 83:8370-8374. 
55. Ma, P.T., Yamamoto, T., Goldstein, J.L., and Brown, M.S. 1986. Increased mRNA for low 
density lipoprotein receptor in livers of rabbits treated with 17 alpha-ethinyl estradiol. Proc 
Natl Acad Sci U S A 83:792-796. 
56. Brunzell, J.D., Davidson, M., Furberg, C.D., Goldberg, R.B., Howard, B.V., Stein, J.H., and 
Witztum, J.L. 2008. Lipoprotein management in patients with cardiometabolic risk: 
consensus conference report from the American Diabetes Association and the American 
College of Cardiology Foundation. J Am Coll Cardiol 51:1512-1524. 
57. Brown, M.S., and Goldstein, J.L. 1979. Receptor-mediated endocytosis: insights from the 
lipoprotein receptor system. Proc Natl Acad Sci U S A 76:3330-3337. 
117 
 
58. Pullinger, C.R., North, J.D., Teng, B.B., Rifici, V.A., Ronhild de Brito, A.E., and Scott, J. 
1989. The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of 
secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J 
Lipid Res 30:1065-1077. 
59. Powell, L.M., Wallis, S.C., Pease, R.J., Edwards, Y.H., Knott, T.J., and Scott, J. 1987. A 
novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell 
50:831-840. 
60. Teng, B., Burant, C.F., and Davidson, N.O. 1993. Molecular cloning of an apolipoprotein B 
messenger RNA editing protein. Science 260:1816-1819. 
61. Dutta, R., Singh, U., Li, T.B., Fornage, M., and Teng, B.B. 2003. Hepatic gene expression 
profiling reveals perturbed calcium signaling in a mouse model lacking both LDL receptor 
and Apobec1 genes. Atherosclerosis 169:51-62. 
62. Mak, S., Sun, H., Acevedo, F., Shimmin, L.C., Zhao, L., Teng, B.B., and Hixson, J.E. 2010. 
Differential expression of genes in the calcium-signaling pathway underlies lesion 
development in the LDb mouse model of atherosclerosis. Atherosclerosis 213:40-51. 
63. Singh, U., Zhong, S., Xiong, M., Li, T.B., Sniderman, A., and Teng, B.B. 2004. Increased 
plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated 
with susceptibility to atherosclerosis in mice. Clin Sci (Lond) 106:421-432. 
64. Hoenig, M.R. 2008. Implications of the obesity epidemic for lipid-lowering therapy: non-
HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. Vasc 
Health Risk Manag 4:143-156. 
65. Cui, Y., Blumenthal, R.S., Flaws, J.A., Whiteman, M.K., Langenberg, P., Bachorik, P.S., 
and Bush, T.L. 2001. Non-high-density lipoprotein cholesterol level as a predictor of 
cardiovascular disease mortality. Arch Intern Med 161:1413-1419. 
66. Scharnagl, H., Nauck, M., Wieland, H., and Marz, W. 2001. The Friedewald formula 
underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 39:426-431. 
118 
 
67. Contois, J.H., McConnell, J.P., Sethi, A.A., Csako, G., Devaraj, S., Hoefner, D.M., and 
Warnick, G.R. 2009. Apolipoprotein B and cardiovascular disease risk: position statement 
from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best 
Practices. Clin Chem 55:407-419. 
68. Lamarche, B., Moorjani, S., Cantin, B., Dagenais, G.R., Lupien, P.J., and Despres, J.P. 1995. 
[Cardiovascular study in Quebec: importance of apolipoprotein B and insulinemia in the risk 
evaluation for myocardial ischemia]. Union Med Can 124:17-21. 
69. van Lennep, J.E., Westerveld, H.T., van Lennep, H.W., Zwinderman, A.H., Erkelens, D.W., 
and van der Wall, E.E. 2000. Apolipoprotein concentrations during treatment and recurrent 
coronary artery disease events. Arterioscler Thromb Vasc Biol 20:2408-2413. 
70. Pischon, T., Girman, C.J., Sacks, F.M., Rifai, N., Stampfer, M.J., and Rimm, E.B. 2005. 
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary 
heart disease in men. Circulation 112:3375-3383. 
71. Gotto, A.M., Jr., Whitney, E., Stein, E.A., Shapiro, D.R., Clearfield, M., Weis, S., Jou, J.Y., 
Langendorfer, A., Beere, P.A., Watson, D.J., et al. 2000. Relation between baseline and on-
treatment lipid parameters and first acute major coronary events in the Air Force/Texas 
Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101:477-484. 
72. Pontrelli, L., Sidiropoulos, K.G., and Adeli, K. 2004. Translational control of apolipoprotein 
B mRNA: regulation via cis elements in the 5' and 3' untranslated regions. Biochemistry 
43:6734-6744. 
73. Sidiropoulos, K.G., Meshkani, R., Avramoglu-Kohen, R., and Adeli, K. 2007. Insulin 
inhibition of apolipoprotein B mRNA translation is mediated via the PI-3 kinase/mTOR 
signaling cascade but does not involve internal ribosomal entry site (IRES) initiation. Arch 
Biochem Biophys 465:380-388. 
74. Sidiropoulos, K.G., Pontrelli, L., and Adeli, K. 2005. Insulin-mediated suppression of 
apolipoprotein B mRNA translation requires the 5' UTR and is characterized by decreased 
119 
 
binding of an insulin-sensitive 110-kDa 5' UTR RNA-binding protein. Biochemistry 
44:12572-12581. 
75. Berriot-Varoqueaux, N., Dannoura, A.H., Moreau, A., Verthier, N., Sassolas, A., Cadiot, G., 
Lachaux, A., Munck, A., Schmitz, J., Aggerbeck, L.P., et al. 2001. Apolipoprotein B48 
glycosylation in abetalipoproteinemia and Anderson's disease. Gastroenterology 121:1101-
1108. 
76. Segrest, J.P., Jones, M.K., and Dashti, N. 1999. N-terminal domain of apolipoprotein B has 
structural homology to lipovitellin and microsomal triglyceride transfer protein: a "lipid 
pocket" model for self-assembly of apob-containing lipoprotein particles. J Lipid Res 
40:1401-1416. 
77. Hussain, M.M., Bakillah, A., Nayak, N., and Shelness, G.S. 1998. Amino acids 430-570 in 
apolipoprotein B are critical for its binding to microsomal triglyceride transfer protein. J Biol 
Chem 273:25612-25615. 
78. Rava, P., Ojakian, G.K., Shelness, G.S., and Hussain, M.M. 2006. Phospholipid transfer 
activity of microsomal triacylglycerol transfer protein is sufficient for the assembly and 
secretion of apolipoprotein B lipoproteins. J Biol Chem 281:11019-11027. 
79. Borchardt, R.A., and Davis, R.A. 1987. Intrahepatic assembly of very low density 
lipoproteins. Rate of transport out of the endoplasmic reticulum determines rate of secretion. 
J Biol Chem 262:16394-16402. 
80. Bostrom, K., Wettesten, M., Boren, J., Bondjers, G., Wiklund, O., and Olofsson, S.O. 1986. 
Pulse-chase studies of the synthesis and intracellular transport of apolipoprotein B-100 in 
Hep G2 cells. J Biol Chem 261:13800-13806. 
81. Yeung, S.J., Chen, S.H., and Chan, L. 1996. Ubiquitin-proteasome pathway mediates 
intracellular degradation of apolipoprotein B. Biochemistry 35:13843-13848. 
120 
 
82. Fisher, E.A., Zhou, M., Mitchell, D.M., Wu, X., Omura, S., Wang, H., Goldberg, A.L., and 
Ginsberg, H.N. 1997. The degradation of apolipoprotein B100 is mediated by the ubiquitin-
proteasome pathway and involves heat shock protein 70. J Biol Chem 272:20427-20434. 
83. Gusarova, V., Caplan, A.J., Brodsky, J.L., and Fisher, E.A. 2001. Apoprotein B degradation 
is promoted by the molecular chaperones hsp90 and hsp70. J Biol Chem 276:24891-24900. 
84. Oyadomari, S., Yun, C., Fisher, E.A., Kreglinger, N., Kreibich, G., Oyadomari, M., Harding, 
H.P., Goodman, A.G., Harant, H., Garrison, J.L., et al. 2006. Cotranslocational degradation 
protects the stressed endoplasmic reticulum from protein overload. Cell 126:727-739. 
85. Hrizo, S.L., Gusarova, V., Habiel, D.M., Goeckeler, J.L., Fisher, E.A., and Brodsky, J.L. 
2007. The Hsp110 molecular chaperone stabilizes apolipoprotein B from endoplasmic 
reticulum-associated degradation (ERAD). J Biol Chem 282:32665-32675. 
86. Fisher, E.A., and Williams, K.J. 2008. Autophagy of an oxidized, aggregated protein beyond 
the ER: a pathway for remarkably late-stage quality control. Autophagy 4:721-723. 
87. Rutledge, A.C., Su, Q., and Adeli, K. 2010. Apolipoprotein B100 biogenesis: a complex 
array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly. 
Biochem Cell Biol 88:251-267. 
88. Rutledge, A.C., Qiu, W., Zhang, R., Kohen-Avramoglu, R., Nemat-Gorgani, N., and Adeli, 
K. 2009. Mechanisms targeting apolipoprotein B100 to proteasomal degradation: evidence 
that degradation is initiated by BiP binding at the N terminus and the formation of a p97 
complex at the C terminus. Arterioscler Thromb Vasc Biol 29:579-585. 
89. Fisher, E.A. 2012. The degradation of apolipoprotein B100: Multiple opportunities to 
regulate VLDL triglyceride production by different proteolytic pathways. Biochim Biophys 
Acta. 
90. Ohsaki, Y., Cheng, J., Fujita, A., Tokumoto, T., and Fujimoto, T. 2006. Cytoplasmic lipid 
droplets are sites of convergence of proteasomal and autophagic degradation of 
apolipoprotein B. Mol Biol Cell 17:2674-2683. 
121 
 
91. Ohsaki, Y., Cheng, J., Suzuki, M., Fujita, A., and Fujimoto, T. 2008. Lipid droplets are 
arrested in the ER membrane by tight binding of lipidated apolipoprotein B-100. J Cell Sci 
121:2415-2422. 
92. Qiu, W., Zhang, J., Dekker, M.J., Wang, H., Huang, J., Brumell, J.H., and Adeli, K. 2011. 
Hepatic autophagy mediates endoplasmic reticulum stress-induced degradation of misfolded 
apolipoprotein B. Hepatology 53:1515-1525. 
93. Le May, C., Kourimate, S., Langhi, C., Chetiveaux, M., Jarry, A., Comera, C., Collet, X., 
Kuipers, F., Krempf, M., Cariou, B., et al. 2009. Proprotein convertase subtilisin kexin type 
9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 
29:684-690. 
94. Amalfitano, A., Hauser, M.A., Hu, H., Serra, D., Begy, C.R., and Chamberlain, J.S. 1998. 
Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 
genes deleted. J Virol 72:926-933. 
95. Teng, B.B., Ochsner, S., Zhang, Q., Soman, K.V., Lau, P.P., and Chan, L. 1999. Mutational 
analysis of apolipoprotein B mRNA editing enzyme (APOBEC1). structure-function 
relationships of RNA editing and dimerization. J Lipid Res 40:623-635. 
96. Sniderman, A.D., and Marcovina, S.M. 2006. Apolipoprotein A1 and B. Clin Lab Med 
26:733-750. 
97. Ouguerram, K., Chetiveaux, M., Zair, Y., Costet, P., Abifadel, M., Varret, M., Boileau, C., 
Magot, T., and Krempf, M. 2004. Apolipoprotein B100 metabolism in autosomal-dominant 
hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 
24:1448-1453. 
98. Lalanne, F., Lambert, G., Amar, M.J., Chetiveaux, M., Zair, Y., Jarnoux, A.L., Ouguerram, 
K., Friburg, J., Seidah, N.G., Brewer, H.B., Jr., et al. 2005. Wild-type PCSK9 inhibits LDL 
clearance but does not affect apoB-containing lipoprotein production in mouse and cultured 
cells. J Lipid Res 46:1312-1319. 
122 
 
99. Lambert, G., Jarnoux, A.L., Pineau, T., Pape, O., Chetiveaux, M., Laboisse, C., Krempf, M., 
and Costet, P. 2006. Fasting induces hyperlipidemia in mice overexpressing proprotein 
convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein 
hepatic output by the low-density lipoprotein receptor. Endocrinology 147:4985-4995. 
100. Everett, R.S., Hodges, B.L., Ding, E.Y., Xu, F., Serra, D., and Amalfitano, A. 2003. Liver 
toxicities typically induced by first-generation adenoviral vectors can be reduced by use of 
E1, E2b-deleted adenoviral vectors. Hum Gene Ther 14:1715-1726. 
101. Zaid, A., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Chamberland, A., Hamelin, J., 
Tremblay, M., Jacques, H., Jin, W., Davignon, J., et al. 2008. Proprotein convertase 
subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor 
degradation and critical role in mouse liver regeneration. Hepatology 48:646-654. 
102. Seiradake, E., Henaff, D., Wodrich, H., Billet, O., Perreau, M., Hippert, C., Mennechet, F., 
Schoehn, G., Lortat-Jacob, H., Dreja, H., et al. 2009. The cell adhesion molecule "CAR" and 
sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog 
5:e1000277. 
103. Benjannet, S., Rhainds, D., Hamelin, J., Nassoury, N., and Seidah, N.G. 2006. The 
proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional 
consequences of natural mutations and post-translational modifications. J Biol Chem 
281:30561-30572. 
104. Lagace, T.A., Curtis, D.E., Garuti, R., McNutt, M.C., Park, S.W., Prather, H.B., Anderson, 
N.N., Ho, Y.K., Hammer, R.E., and Horton, J.D. 2006. Secreted PCSK9 decreases the 
number of LDL receptors in hepatocytes and in livers of parabiotic mice. The Journal of 
clinical investigation 116:2995-3005. 
105. Maxwell, K.N., Fisher, E.A., and Breslow, J.L. 2005. Overexpression of PCSK9 accelerates 
the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad 
Sci U S A 102:2069-2074. 
123 
 
106. Park, S.W., Moon, Y.A., and Horton, J.D. 2004. Post-transcriptional regulation of low 
density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in 
mouse liver. J Biol Chem 279:50630-50638. 
107. Teng, B.-B., Song, L.-Z., and Chan, L. 1995. Mutations in the leucine-rich motif in 
apolipoprotein mRNA editing enzyme catalytic polypeptide 1 eliminate apoB mRNA editing 
activity. Circulation Suppl. 92:I-165. 
108. Soderberg, O., Gullberg, M., Jarvius, M., Ridderstrale, K., Leuchowius, K.J., Jarvius, J., 
Wester, K., Hydbring, P., Bahram, F., Larsson, L.G., et al. 2006. Direct observation of 
individual endogenous protein complexes in situ by proximity ligation. Nature methods 
3:995-1000. 
109. Ohsaki, Y., Cheng, J., Fujita, A., Tokumoto, T., and Fujimoto, T. 2006. Cytoplasmic lipid 
droplets are sites of convergence of proteasomal and autophagic degradation of 
apolipoprotein B. Molecular biology of the cell 17:2674-2683. 
110. Glick, D., Barth, S., and Macleod, K.F. 2010. Autophagy: cellular and molecular 
mechanisms. The Journal of pathology 221:3-12. 
111. Pan, M., Maitin, V., Parathath, S., Andreo, U., Lin, S.X., St Germain, C., Yao, Z., Maxfield, 
F.R., Williams, K.J., and Fisher, E.A. 2008. Presecretory oxidation, aggregation, and 
autophagic destruction of apoprotein-B: a pathway for late-stage quality control. 
Proceedings of the National Academy of Sciences of the United States of America 105:5862-
5867. 
112. Crunkhorn, S. 2012. Trial watch: PCSK9 antibody reduces LDL cholesterol. Nat Rev Drug 
Discov 11:11. 
113. Burman, C., and Ktistakis, N.T. 2010. Regulation of autophagy by phosphatidylinositol 3-
phosphate. FEBS Lett 584:1302-1312. 
114. Rabinowitz, J.D., and White, E. 2010. Autophagy and metabolism. Science 330:1344-1348. 
124 
 
115. Baehrecke, E.H. 2005. Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol 
6:505-510. 
116. Chang, Y.Y., and Neufeld, T.P. 2010. Autophagy takes flight in Drosophila. FEBS Lett 
584:1342-1349. 
117. Cao, Y., and Klionsky, D.J. 2007. Physiological functions of Atg6/Beclin 1: a unique 
autophagy-related protein. Cell Res 17:839-849. 
118. Chen, Y., and Klionsky, D.J. 2011. The regulation of autophagy - unanswered questions. J 
Cell Sci 124:161-170. 
119. Razani, B., Feng, C., Coleman, T., Emanuel, R., Wen, H., Hwang, S., Ting, J.P., Virgin, 
H.W., Kastan, M.B., and Semenkovich, C.F. 2012. Autophagy links inflammasomes to 
atherosclerotic progression. Cell Metab 15:534-544. 
120. Ouimet, M., Franklin, V., Mak, E., Liao, X., Tabas, I., and Marcel, Y.L. 2011. Autophagy 
regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell 
Metab 13:655-667. 
121. Shelness, G.S., and Ledford, A.S. 2005. Evolution and mechanism of apolipoprotein B-
containing lipoprotein assembly. Curr Opin Lipidol 16:325-332. 
 
125 
 
 VITA 
Hua Sun, the son of Youshou Sun and Qiuyun Hua, was born on March 10th, 1978 in 
Nanjing, the capital city of Jiangsu Province, People’s Republic of China. In 1996, he graduated 
from Nanjing No. 9 High School in Nanjing. In the fall of that year, he entered Nanjing Medical 
University. He received the degree of Bachelor of Medicine from Nanjing Medical University in July 
of 2001. After that he, he received his degree of Master of Science from the same university in 2004. 
Then, Hua worked as a microbiologist in Nanjing Center for Diseases Control and Prevention for 2 
years.  In August 2006, Hua entered the University of Texas Health Science Center at Houston, 
Graduate School of Biomedical Sciences where he conducted her research project in the Brown 
Foundation of Molecular Medicine, at the University of Texas Health Science Center at Houston.  
